1
|
Gloaguen E, Dizier MH, Boissel M, Rocheleau G, Canouil M, Froguel P, Tichet J, Roussel R, Julier C, Balkau B, Mathieu F. General regression model: A "model-free" association test for quantitative traits allowing to test for the underlying genetic model. Ann Hum Genet 2019; 84:280-290. [PMID: 31834638 DOI: 10.1111/ahg.12372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Revised: 11/19/2019] [Accepted: 11/20/2019] [Indexed: 11/26/2022]
Abstract
Most genome-wide association studies used genetic-model-based tests assuming an additive mode of inheritance, leading to underpowered association tests in case of departure from additivity. The general regression model (GRM) association test proposed by Fisher and Wilson in 1980 makes no assumption on the genetic model. Interestingly, it also allows formal testing of the underlying genetic model. We conducted a simulation study of quantitative traits to compare the power of the GRM test to the classical linear regression tests, the maximum of the three statistics (MAX), and the allele-based (allelic) tests. Simulations were performed on two samples sizes, using a large panel of genetic models, varying genetic models, minor allele frequencies, and the percentage of explained variance. In case of departure from additivity, the GRM was more powerful than the additive regression tests (power gain reaching 80%) and had similar power when the true model is additive. GRM was also as or more powerful than the MAX or allelic tests. The true simulated model was mostly retained by the GRM test. Application of GRM to HbA1c illustrates its gain in power. To conclude, GRM increases power to detect association for quantitative traits, allows determining the genetic model and is easily applicable.
Collapse
Affiliation(s)
- Emilie Gloaguen
- Inserm UMRS-958, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Marie-Hélène Dizier
- Inserm UMR-946, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Mathilde Boissel
- Université de Lille, UMR 8199 - EGID, Lille, France.,CNRS, Paris, France.,Institut Pasteur de Lille, Lille, France
| | - Ghislain Rocheleau
- Université de Lille, UMR 8199 - EGID, Lille, France.,CNRS, Paris, France.,Institut Pasteur de Lille, Lille, France
| | - Mickaël Canouil
- Université de Lille, UMR 8199 - EGID, Lille, France.,CNRS, Paris, France.,Institut Pasteur de Lille, Lille, France
| | - Philippe Froguel
- Université de Lille, UMR 8199 - EGID, Lille, France.,CNRS, Paris, France.,Institut Pasteur de Lille, Lille, France.,Department of Genomics of Common Disease, Imperial College London, London, United Kingdom
| | | | - Ronan Roussel
- Inserm U1138, Centre de Recherche des Cordeliers, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Diabetology, Endocrinology and Nutrition Department, DHU FIRE, Hôpital Bichat, AP-HP, Paris, France
| | -
- Inserm UMRS-958, Paris, France
| | - Cécile Julier
- Inserm UMRS-958, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | | | - Flavie Mathieu
- Mission Associations Recherche & Société - Inserm Siège, DISC, Paris, France.,Paris Diderot, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
2
|
Balkau B, Roussel R, Wagner S, Tichet J, Froguel P, Fagherazzi G, Bonnet F. Transmission of Type 2 diabetes to sons and daughters: the D.E.S.I.R. cohort. Diabet Med 2017; 34:1615-1622. [PMID: 28792638 DOI: 10.1111/dme.13446] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/04/2017] [Indexed: 01/15/2023]
Abstract
AIMS To document the family transmission of Type 2 diabetes to men and women. METHOD The French D.E.S.I.R. cohort followed men and women over 9 years, with 3-yearly testing for incident Type 2 diabetes. First- and/or second-degree family histories of diabetes were available for 2187 men and 2282 women. Age-adjusted hazard ratios were estimated for various family members and groupings of family members, as well as for a genetic diabetes risk score, based on 65 diabetes-associated loci. RESULTS Over 9 years, 136 men and 63 women had incident Type 2 diabetes. The hazard ratios for diabetes associated with having a first-degree family member with diabetes (parents, siblings, children) differed between men [1.21 (95% CI 0.80, 1.85)] and women [3.02 (95% CI 1.83, 4.99); Pinteraction =0.006]. The genetic risk score was predictive of diabetes in both men and women, with similar hazard ratios 1.10 (95% CI 1.06, 1.15) and 1.08 (95% CI 1.02, 1.14) respectively, for each additional at-risk allele. In women, the risk associated with having a family member with diabetes persisted after adjusting for the genetic score. CONCLUSION Women with a family history of diabetes (paternal or maternal) were at risk of developing Type 2 diabetes and this risk was independent of a genetic score; in contrast, for men, there was no association. Diabetes screening and prevention may need to more specifically target women with diabetes in their family, but further studies are required as the number of people with diabetes in this study was small.
Collapse
Affiliation(s)
- B Balkau
- CESP, Faculty of Medicine, University Paris-South
- Faculty of Medicine, University Versailles-St Quentin
- INSERM U1018, Faculty of Medicine, University Paris-Saclay, Villejuif
| | - R Roussel
- Centre de Recherche des Cordeliers, INSERM, Bichat Hospital, Paris
| | - S Wagner
- CESP, Faculty of Medicine, University Paris-South
- Faculty of Medicine, University Versailles-St Quentin
- INSERM U1018, Faculty of Medicine, University Paris-Saclay, Villejuif
| | | | - P Froguel
- CNRS, UMR8199, Pasteur Institute of Lille, European Genomic Institute for Diabetes, Lille University, Lille, France
- Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, UK
| | - G Fagherazzi
- CESP, Faculty of Medicine, University Paris-South
- Faculty of Medicine, University Versailles-St Quentin
- INSERM U1018, Faculty of Medicine, University Paris-Saclay, Villejuif
- Gustave Roussy Institute, Villejuif
| | - F Bonnet
- CESP, Faculty of Medicine, University Paris-South
- Faculty of Medicine, University Versailles-St Quentin
- INSERM U1018, Faculty of Medicine, University Paris-Saclay, Villejuif
- CHU Rennes, University Rennes 1, Rennes, France
| |
Collapse
|
3
|
Bonnet F, Gastaldelli A, Pihan-Le Bars F, Natali A, Roussel R, Petrie J, Tichet J, Marre M, Fromenty B, Balkau B. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens 2017; 35:493-500. [PMID: 27984413 DOI: 10.1097/hjh.0000000000001204] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVE We hypothesized that liver markers and the fatty liver index (FLI) are predictive of incident hypertension and that hepatic insulin resistance plays a role. METHODS The association between liver markers and incident hypertension was analysed in two longitudinal studies of normotensive individuals, 2565 from the 9-year data from an epidemiological study on the insulin resistance cohort and the 321 from the 3-year 'Relationship between Insulin Sensitivity and Cardiovascular disease' cohort who had a measure of endogenous glucose production. The FLI is calculated from BMI, waist circumference, triglycerides and gamma-glutamyltransferase (GGT) and the hepatic insulin resistance index from endogenous glucose production and fasting insulin. RESULTS The incidence of hypertension increased across the quartiles groups of both baseline GGT and alanine aminotransferase. After adjustment for sex, age, waist circumference, fasting glucose, smoking and alcohol intake, only GGT was significantly related with incident hypertension [standardized odds ratio: 1.21; 95% confidence interval (1.10-1.34); P = 0.0001]. The change in GGT levels over the follow-up was also related with an increased risk of hypertension, independently of changes in body weight. FLI analysed as a continuous value, or FLI at least 60 at baseline were predictive of incident hypertension in the multivariable model. In the RISC cohort, the hepatic insulin resistance index was positively related with the risk of 3-year incident hypertension [standardized odds ratio: 1.54 (1.07-2.22); P = 0.02]. CONCLUSION Baseline GGT and FLI, as well as an increase in GGT over time, were associated with the risk of incident hypertension. Enhanced hepatic insulin resistance predicted the onset of hypertension and may be a link between liver markers and hypertension.
Collapse
Affiliation(s)
- Fabrice Bonnet
- aService Endocrinologie-Diabétologie, CHU Rennes, Université Rennes 1, Rennes bINSERM, Centre for Research in Epidemiology and Population Health (CESP), U1018 cUniversity Paris-Sud, University Versailles Saint-Quentin, UMRS 1018, Paris, France dClinical Physiology CNR, Cardiometabolic Risk Laboratory eDepartment of Internal Medicine, University of Pisa, Pisa, Italy fINSERM U1138 gAP-HP, Hôpital Bichat, Diabetology Endocrinology Nutrition, Université Paris Diderot, Paris, France hInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK iIRSA, La Riche jINSERM, U991, Université de Rennes 1, Rennes, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Arredouani A, Stocchero M, Culeddu N, Moustafa JES, Tichet J, Balkau B, Brousseau T, Manca M, Falchi M. Erratum. Metabolomic Profile of Low-Copy Number Carriers at the Salivary α-Amylase Gene Suggests a Metabolic Shift Toward Lipid-Based Energy Production. Diabetes 2016;65:3362-3368. Diabetes 2017; 66:1097. [PMID: 28193788 PMCID: PMC5360297 DOI: 10.2337/db17-er04a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Nicolas A, Aubert R, Bellili-Muñoz N, Balkau B, Bonnet F, Tichet J, Velho G, Marre M, Roussel R, Fumeron F. T-cadherin gene variants are associated with type 2 diabetes and the Fatty Liver Index in the French population. Diabetes & Metabolism 2017; 43:33-39. [DOI: 10.1016/j.diabet.2016.05.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Revised: 04/26/2016] [Accepted: 05/10/2016] [Indexed: 11/30/2022]
|
6
|
Azevedo Da Silva M, Balkau B, Roussel R, Tichet J, Fumeron F, Fagherazzi G, Nabi H. Longitudinal association of antidepressant medication use with metabolic syndrome: Results of a 9-year follow-up of the D.E.S.I.R. cohort study. Psychoneuroendocrinology 2016; 74:34-45. [PMID: 27567119 DOI: 10.1016/j.psyneuen.2016.08.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Revised: 08/19/2016] [Accepted: 08/19/2016] [Indexed: 12/18/2022]
Abstract
OBJECTIVE To examine longitudinal associations between antidepressant medication use and the metabolic syndrome (MetS). METHODS 5014 participants (49.8% were men) from the D.E.S.I.R. cohort study, aged 30-65 years at baseline in 1994-1996, were followed over 9 years at 3-yearly intervals (1997-1999, 2000-2002, and 2003-2005). Antidepressant use and MetS, defined by the National Cholesterol Education Program Adult Treatment Panel III criteria (NCEP-ATP III) and the American Heart Association and the National Heart, Lung and Blood Institute (AHA/NHLBI) criteria, were assessed concurrently at four medical examinations. RESULTS In fully-adjusted longitudinal logistic regression analyses based on generalized estimating equations, antidepressant users had a 9% (p=0.011) and a 6% (p=0.036) greater annual increase in the odds of having the MetS defined by NCEP-ATP III and AHA/NHLBI criteria respectively. Sex-specific analyses showed that this association was confined to men only. When the different types of antidepressant were considered, men who used selective serotonin reuptake inhibitors (SSRIs), imipramine type antidepressants or "other" antidepressants had a 52% (p=0.028), 31% (p=0.011), and 16% (p=0.016) greater annual increase in the odds of having the MetS over time compared to non-users, respectively. These associations depended on the definition of the MetS. CONCLUSIONS Our longitudinal data showed that antidepressant use was associated with an increased odds of having the MetS in men but not in women and this was mainly for SSRIs, imipramine type and "other" antidepressants. People on antidepressants may need to be checked regularly for the elements of the metabolic syndrome treatable by change in diet, physical activity and/or by medication therapy.
Collapse
Affiliation(s)
- Marine Azevedo Da Silva
- INSERM, Centre for Research in Epidemiology and Population Health, U1018, F-94807, Villejuif, France; University Versailles Saint-Quentin-en-Yvelines, UMRS 1018, F-78035, Versailles, France.
| | - Beverley Balkau
- INSERM, Centre for Research in Epidemiology and Population Health, U1018, F-94807, Villejuif, France; University Versailles Saint-Quentin-en-Yvelines, UMRS 1018, F-78035, Versailles, France; University Paris Sud 11, UMRS 1018, F-94807, Villejuif, France
| | - Ronan Roussel
- Service d'Endocrinologie, Diabétologie et Nutrition, DHU FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM, Centre de Recherche des Cordeliers, U1138, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Jean Tichet
- Institut inter Régional pour la Santé (IRSA), La Riche, France
| | - Frédéric Fumeron
- INSERM, Centre de Recherche des Cordeliers, U1138, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Guy Fagherazzi
- INSERM, Centre for Research in Epidemiology and Population Health, U1018, F-94807, Villejuif, France; University Paris Sud 11, UMRS 1018, F-94807, Villejuif, France
| | - Hermann Nabi
- INSERM, Centre for Research in Epidemiology and Population Health, U1018, F-94807, Villejuif, France; University Versailles Saint-Quentin-en-Yvelines, UMRS 1018, F-78035, Versailles, France
| | | |
Collapse
|
7
|
Arredouani A, Stocchero M, Culeddu N, Moustafa JES, Tichet J, Balkau B, Brousseau T, Manca M, Falchi M. Metabolomic Profile of Low-Copy Number Carriers at the Salivary α-Amylase Gene Suggests a Metabolic Shift Toward Lipid-Based Energy Production. Diabetes 2016; 65:3362-3368. [PMID: 27436124 DOI: 10.2337/db16-0315] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Accepted: 07/06/2016] [Indexed: 12/28/2022]
Abstract
Low serum salivary amylase levels have been associated with a range of metabolic abnormalities, including obesity and insulin resistance. We recently suggested that a low copy number at the AMY1 gene, associated with lower enzyme levels, also increases susceptibility to obesity. To advance our understanding of the effect of AMY1 copy number variation on metabolism, we compared the metabolomic signatures of high- and low-copy number carriers. We analyzed, using mass spectrometry and nuclear magnetic resonance (NMR), the sera of healthy normal-weight women carrying either low-AMY1 copies (LAs: four or fewer copies; n = 50) or high-AMY1 copies (HAs: eight or more copies; n = 50). Best-fitting multivariate models (empirical P < 1 × 10-3) of mass spectrometry and NMR data were concordant in showing differences in lipid metabolism between the two groups. In particular, LA carriers showed lower levels of long- and medium-chain fatty acids, and higher levels of dicarboxylic fatty acids and 2-hydroxybutyrate (a known marker of glucose malabsorption). Taken together, these observations suggest increased metabolic reliance on fatty acids in LA carriers through β- and ω-oxidation and reduced cellular glucose uptake with consequent diversion of acetyl-CoA into ketogenesis. Our observations are in line with previously reported delayed glucose uptake in LA carriers after starch consumption. Further functional studies are needed to extrapolate from our findings to implications for biochemical pathways.
Collapse
Affiliation(s)
- Abdelilah Arredouani
- Hamad Ben Khalifa University, Qatar Biomedical Research Institute, Diabetes Research Centre, Qatar Foundation, Doha, Qatar
- Department of Genomics of Common Disease, Imperial College London, U.K
| | | | - Nicola Culeddu
- Istituto di Chimica Biomolecolare, Laboratory of Nuclear Magnetic Resonance, Consiglio Nazionale delle Ricerche, Sassari, Italy
| | - Julia El-Sayed Moustafa
- Department of Twin Research & Genetic Epidemiology, King's College London, St. Thomas' Hospital Campus, London, U.K
| | | | - Jean Tichet
- Institut Inter-Régional Pour la Santé, La Riche, France
| | - Beverley Balkau
- Centre de Recherche en Epidémiologie et Santé des Populations, Le Centre de Recherche en Epidémiologie et Santé des Populations, INSERM U1018, Renal and Cardiovascular Epidemiology, Villejuif, France
- Universities Versailles-St. Quentin and Paris-Sud, UMRS 1018, Villejuif, France
| | - Thierry Brousseau
- UF8832, Biochimie Automatisée, Pôle de Biologie Pathologie Génétique, Centre Hospitalier Régional Universitaire, Lille, France
| | - Marco Manca
- Experimental Vascular Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, the Netherlands
- Accelerators & Technology Sector, CERN, Geneva, Switzerland
| | - Mario Falchi
- Department of Genomics of Common Disease, Imperial College London, U.K.
- Department of Twin Research & Genetic Epidemiology, King's College London, St. Thomas' Hospital Campus, London, U.K
| |
Collapse
|
8
|
Chakhtoura Z, Laki F, Bernadet M, Cherifi I, Chiche A, Pigat N, Bernichtein S, Courtillot C, Boutillon F, Bièche I, Vacher S, Tanguy ML, Bissery A, Grouthier V, Camparo P, Foretz M, Do Cruzeiro M, Pierre R, Rakotozafy F, Tichet J, Tejedor I, Guidotti JE, Sigal-Zafrani B, Goffin V, Touraine P. Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk. J Clin Endocrinol Metab 2016; 101:4449-4460. [PMID: 27575941 DOI: 10.1210/jc.2016-2372] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT In a cohort of 95 women with multiple breast fibroadenomas (MFAs), we recently identified patients harboring germline heterozygous variants of the prolactin receptor (PRLR) exhibiting constitutive activity (PRLRI146L and PRLRI176V). OBJECTIVE This study sought to better delineate the potential role of PRLR gain-of-function variants in benign and malignant mammary tumorigenesis. DESIGN This was an observational study and transgenic mouse model analysis. SETTING The study took place at the Department of Endocrinology, Reproductive Disorders and Rare Gynecologic Diseases, Pitié Salpêtrière, Paris, and Inserm Unit 1151, Paris. PATIENTS OR OTHER PARTICIPANTS We generated a second MFA cohort (n = 71) as well as a group of control subjects (n = 496) and a cohort of women with breast cancer (n = 119). We also generated two transgenic mouse models carrying the coding sequences of human PRLRI146L or PRLRWT. INTERVENTION We aimed to determine the prevalence of PRLR variants in these three populations and to uncover any association of the latter with specific tumor pattern, especially in patients with breast cancer. RESULTS This study did not highlight a higher prevalence of PRLR variants in the MFA group and in the breast cancer group compared with control subjects. Transgenic mice expressing PRLRI146L exhibited very mild histological mammary phenotype but tumors were never observed. CONCLUSION PRLRI146L and PRLRI176V variants are not associated with breast cancer or MFA risk. However, one cannot exclude that low but sustained PRLR signaling may facilitate or contribute to pathological development driven by oncogenic pathways. Long-term patient follow-up should help to address this issue.
Collapse
Affiliation(s)
- Zeina Chakhtoura
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Fatima Laki
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Marie Bernadet
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Ibtissem Cherifi
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Aurélie Chiche
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Natascha Pigat
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Sophie Bernichtein
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Carine Courtillot
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Florence Boutillon
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Ivan Bièche
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Sophie Vacher
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Marie-Laure Tanguy
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Anne Bissery
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Virginie Grouthier
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Philippe Camparo
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Marc Foretz
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Marcio Do Cruzeiro
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Rémi Pierre
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Fabienne Rakotozafy
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Jean Tichet
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Isabelle Tejedor
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Jacques-Emmanuel Guidotti
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Brigitte Sigal-Zafrani
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Vincent Goffin
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| | - Philippe Touraine
- Institut E3M-ICAN, Department of Endocrinology and Reproductive Medicine (Z.C., C.C., V.Gr., I.T., P.T.), Hôpitaux Universitaires Pitié Salpêtrière Charles Foix, Centre des Pathologies Gynécologiques Rares, Firendo, Université Pierre et Marie Curie, 75013 Paris, France; Department of Oncological Surgery (F.L.), Institut Curie, 75005 Paris, France; Inserm (M.B., I.C., A.C., N.P., S.B., F.B., P.C., J.-E.G., V.G., P.T.), U1151, Institut Necker Enfants Malades, 75993 Paris, France; Université Paris Descartes (M.B., I.C., A.C., N.P., S.B., F.B., M.F., M.D.C., R.P., J.-E. G., V.G.), Sorbonne Paris Cité, France; Department of Genetics (I.B., S.V.), Institut Curie, 75005 Paris, France; Unite de Recherche Clinique (M.-L.T., A.B.), Pitie Salpêtriere Hospital, 75013 Paris, France; Inserm (M.F., M.D.C.), U1016, Institut Cochin, 75014 Paris, France; CNRS (M.F., M.D.C., R.P.), UMR8104, Paris, France; Inter Régional pour la Santé (F.R., J.T.), La Riche, France; and Department of Pathology (B.S.-Z.), Institut Curie, 75005 Paris, France
| |
Collapse
|
9
|
Yengo L, Arredouani A, Marre M, Roussel R, Vaxillaire M, Falchi M, Haoudi A, Tichet J, Balkau B, Bonnefond A, Froguel P. Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling. Mol Metab 2016; 5:918-925. [PMID: 27689004 PMCID: PMC5034686 DOI: 10.1016/j.molmet.2016.08.011] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Revised: 08/12/2016] [Accepted: 08/16/2016] [Indexed: 12/21/2022] Open
Abstract
OBJECTIVE Characterizing specific metabolites in sub-clinical phases preceding the onset of type 2 diabetes to enable efficient preventive and personalized interventions. RESEARCH DESIGN AND METHODS We developed predictive models of type 2 diabetes using two strategies. One strategy focused on the probability of incidence only and was based on logistic regression (MRS1); the other strategy accounted for the age at diagnosis of diabetes and was based on Cox regression (MRS2). We assessed 293 metabolites using non-targeted metabolomics in fasting plasma samples of 1,044 participants (including 231 incident cases over 9 years) used as training population; and fasting serum samples of 128 participants (64 incident cases versus 64 controls) used as validation population. We applied a LASSO-based variable selection aiming at maximizing the out-of-sample area under the receiver operating characteristic curve (AROC) and integrated AROC. RESULTS Sixteen and 17 metabolites were selected for MRS1 and MRS2, respectively, with AROC = 90% and 73% in the training and validation populations, respectively for MRS1. MRS2 had a similar performance and was significantly associated with a younger age of onset of type 2 diabetes (β = -3.44 years per MRS2 SD in the training population, p = 1.56 × 10(-7); β = -4.73 years per MRS2 SD in the validation population, p = 4.04 × 10(-3)). CONCLUSIONS Overall, this study illustrates that metabolomics improves prediction of type 2 diabetes incidence of 4.5% on top of known clinical and biological markers, reaching 90% in total AROC, which is considered the threshold for clinical validity, suggesting it may be used in targeting interventions to prevent type 2 diabetes.
Collapse
Affiliation(s)
- Loic Yengo
- CNRS UMR8199, Pasteur Institute of Lille, Lille, France; European Genomic Institute for Diabetes (EGID), FR-3508, Lille, France; Lille University, France
| | | | - Michel Marre
- INSERM, U1138 (équipe 2: Pathophysiology and Therapeutics of Vascular and Renal Diseases Related to Diabetes, Centre de Recherches des Cordeliers), Paris, France; University Paris 7 Denis Diderot, Sorbonne Paris Cité, France; AP-HP, DHU FIRE, Department of Endocrinology, Diabetology, Nutrition, and Metabolic Diseases, Bichat Claude Bernard Hospital, Paris, France
| | - Ronan Roussel
- INSERM, U1138 (équipe 2: Pathophysiology and Therapeutics of Vascular and Renal Diseases Related to Diabetes, Centre de Recherches des Cordeliers), Paris, France; University Paris 7 Denis Diderot, Sorbonne Paris Cité, France; AP-HP, DHU FIRE, Department of Endocrinology, Diabetology, Nutrition, and Metabolic Diseases, Bichat Claude Bernard Hospital, Paris, France
| | - Martine Vaxillaire
- CNRS UMR8199, Pasteur Institute of Lille, Lille, France; European Genomic Institute for Diabetes (EGID), FR-3508, Lille, France; Lille University, France
| | - Mario Falchi
- Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, UK
| | - Abdelali Haoudi
- Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | | | - Beverley Balkau
- INSERM U-1018, CESP, Renal and Cardiovascular Epidemiology, UVSQ-UPS, Villejuif, France
| | - Amélie Bonnefond
- CNRS UMR8199, Pasteur Institute of Lille, Lille, France; European Genomic Institute for Diabetes (EGID), FR-3508, Lille, France; Lille University, France
| | - Philippe Froguel
- CNRS UMR8199, Pasteur Institute of Lille, Lille, France; European Genomic Institute for Diabetes (EGID), FR-3508, Lille, France; Lille University, France; Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, UK.
| |
Collapse
|
10
|
Roussel R, El Boustany R, Bouby N, Potier L, Fumeron F, Mohammedi K, Balkau B, Tichet J, Bankir L, Marre M, Velho G. Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community. J Clin Endocrinol Metab 2016; 101:2432-9. [PMID: 27049477 PMCID: PMC4891798 DOI: 10.1210/jc.2016-1113] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
CONTEXT Experimental data support a role for vasopressin in metabolic disorders. OBJECTIVE We investigated associations of plasma copeptin, a surrogate of vasopressin, and of allelic variations in the arginine vasopressin-neurophysin II gene with insulin secretion, insulin sensitivity, and the risk for impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM). DESIGN, SETTING, AND PARTICIPANTS We studied 5110 unrelated French men and women from a prospective cohort of the general population (Data from Epidemiological Study on the Insulin Resistance Syndrome cohort, 9-y follow-up). Six single nucleotide polymorphisms were genotyped. MAIN OUTCOME MEASURE Incidence of IFG or T2DM during follow-up. RESULTS The incidence of hyperglycemia (IFG/T2DM) during follow-up by quartiles of baseline plasma copeptin was 11.0% (Q1), 14.5% (Q2), 17.0% (Q3), and 23.5% (Q4), log-rank test P = .003. Participants in the upper quartile of plasma copeptin had significantly lower insulin sensitivity (homeostasis model assessment index) at baseline and during follow-up, as compared with other participants. Cox proportional hazards regression analyses showed significant associations of the CC genotype of rs6084264, the TT genotype of rs2282018, the C-allele of rs2770381, and the CC genotype of rs1410713 with the incidence of hyperglycemia. The genotypes associated with an increased risk of hyperglycemia were also associated with increased plasma copeptin in men but not in women. CONCLUSIONS High plasma copeptin was associated with reduced insulin sensitivity and an increased risk for IFG/T2DM diabetes in this community-based cohort. Moreover, in men, allelic associations support a causal role for vasopressin in these disorders.
Collapse
Affiliation(s)
- Ronan Roussel
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Ray El Boustany
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Nadine Bouby
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Louis Potier
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Frédéric Fumeron
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Kamel Mohammedi
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Beverley Balkau
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Jean Tichet
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Lise Bankir
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Michel Marre
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| | - Gilberto Velho
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers (R.R., R.E.B., N.B., L.P., F.F., K.M., L.B., M.M., G.V.), 75006 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition (R.R., L.P., K.M., M.M.), 75018 Paris, France; Sorbonne Universités, Université Pierre et Marie Curie - Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers (R.E.B., N.B., L.B.), 75006 Paris, France; INSERM Unité de Recherche 1018, Centre de Recherche en Epidémiologie et Santé des Populations, and Université Paris Sud (B.B.), 94800 Villejuif, France; and IRSA (J.T.), 37520 La Riche, France
| |
Collapse
|
11
|
Copin N, Gusto G, Vol S, Rollier S, Lantieri O, Lasfargues G, Tichet J. Perturbation du métabolisme lipidique chez des travailleurs postés consultants de centres d’examens de santé. Presse Med 2016; 45:e145-56. [DOI: 10.1016/j.lpm.2015.12.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Revised: 10/19/2015] [Accepted: 12/17/2015] [Indexed: 12/29/2022] Open
|
12
|
Gusto G, Vol S, Lasfargues G, Voisin V, Bedouet M, Leglu C, Grenier B, Copin N, Lantieri O, Tichet J. [Promote better nutritional behaviours among shift workers with night shift]. Presse Med 2015; 44:e191-201. [PMID: 25704803 DOI: 10.1016/j.lpm.2014.09.024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Revised: 07/21/2014] [Accepted: 09/22/2014] [Indexed: 12/29/2022] Open
Abstract
AIM Shift work, especially including a night shift, is associated with degradation of physical, social and psychosocial health as well as poor well-being. Food imbalance and low physical activity contributed to the negative effects on health. Our objective was to promote a healthier nutritional behaviour according to the French national nutrition and health program recommendations (PNNS). METHODS A one-year nutritional intervention with personalised dietetic counselling was proposed to 235 shift workers with night shift who came for a health prevention exam in one of the centres of the Institut Inter-Régional pour la Santé between 2009 and 2011. The intervention was three dietary interviews: at baseline with definition of goal setting, at 3 months for advice and support and at one-year for the evaluation. At 6 months, a personalised reminder letter was send. Compliance with the PNNS recommendations and level of physical activity were evaluated at baseline and at one-year by a self-administered questionnaire. Changes between baseline and follow-up were compared by paired t-tests or McNemar-tests. RESULTS The rate of follow-up was 57.4%. At the end of the study, subjects improved their compliance with PNNS guidelines concerning sweetened products (P<0.001), water (P=0.02) and salt (P=0.05), increased their leisure physical activity (P=0.001) and decreased their daily energy intakes (P<0.001). CONCLUSION A structured intervention can improve nutritional behaviours of shift workers. This intervention enabled to inform and alert on the risk related to this work schedule and promote better nutritional behaviours.
Collapse
Affiliation(s)
- Gaëlle Gusto
- Institut interrégional pour la santé, 37521 La Riche cedex, France.
| | - Sylviane Vol
- Institut interrégional pour la santé, 37521 La Riche cedex, France
| | - Gérard Lasfargues
- Agence nationale de sécurité sanitaire et de l'alimentation, de l'environnement et du travail, 94701 Maisons-Alfort cedex, France; CHRU, université François-Rabelais, 37132 Tours cedex 01, France
| | - Violaine Voisin
- Institut interrégional pour la santé, 37521 La Riche cedex, France
| | - Martine Bedouet
- Institut interrégional pour la santé, 37521 La Riche cedex, France
| | - Caroline Leglu
- Institut interrégional pour la santé, 37521 La Riche cedex, France
| | | | - Nane Copin
- Institut interrégional pour la santé, 37521 La Riche cedex, France
| | - Olivier Lantieri
- Institut interrégional pour la santé, 37521 La Riche cedex, France
| | - Jean Tichet
- Institut interrégional pour la santé, 37521 La Riche cedex, France
| |
Collapse
|
13
|
Troussard X, Vol S, Cornet E, Bardet V, Couaillac JP, Fossat C, Luce JC, Maldonado E, Siguret V, Tichet J, Lantieri O, Corberand J. Full blood count normal reference values for adults in France. J Clin Pathol 2013; 67:341-4. [DOI: 10.1136/jclinpath-2013-201687] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Gusto G, Vol S, Lasfargues G, Guillaud C, Lantieri O, Tichet J. Précarité et indicateurs de santé chez les sujets en contrat à durée indéterminée à temps plein. Rev Epidemiol Sante Publique 2013. [DOI: 10.1016/j.respe.2013.07.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
15
|
Gusto G, Vol S, Lasfargues G, Guillaud C, Lantieri O, Tichet J. Deprivation and health risk indicators in full-time permanent workers. Eur J Public Health 2013; 24:585-94. [PMID: 24068546 DOI: 10.1093/eurpub/ckt138] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Association between deprivation and health is well established, particularly among unemployed or fixed-term contract or temporary contract subjects. This study aimed to assess if this relationship existed as well in full-time permanent workers. METHODS Biometrical, biological, behavioural and psychosocial health risk indicators and an individual deprivation score, the Evaluation of Precarity and Inequalities in Health Examination Centres score, were recorded from January 2007 to June 2008, in 34 905 full-time permanent workers aged 18-70 years, all volunteers for a free health examination. Comparisons of the behavioural, metabolic, cardiovascular and health risk indicators between quintiles of the deprivation score with adjustments on age and socioeconomic categories were made by covariance analysis or logistic regression. RESULTS For both genders, degradation of nutritional behaviours, metabolic and cardiovascular indicators and health appeared gradually with deprivation, even for deprivation score usually considered as an insignificant value. The absence of only one social support or one social network was associated with a degradation of health. Full-time permanent workers with the poorest health risk indicators had more frequent social exclusion signs. These results were independent of socioeconomic categories and age. CONCLUSION Understanding how deprivation influences health status may lead to more effective interventions to reduce social inequalities in health. The deprivation Evaluation of Precarity and Inequalities in Health Examination Centres score is a relevant tool to detect subjects who could benefit from preventive interventions. Our findings suggest that this deprivation score should be used as a health risk indicator even in full-time permanent workers. Assessing deprivation is useful to design and evaluate specific intervention programmes.
Collapse
Affiliation(s)
- Gaëlle Gusto
- 1 IRSA, département Synergies, 37521 La Riche cedex, France
| | - Sylviane Vol
- 1 IRSA, département Synergies, 37521 La Riche cedex, France
| | - Gérard Lasfargues
- 2 CHRU Université François Rabelais, Médecine et Santé au travail, 37132 Tours cedex 01, France
| | | | | | - Jean Tichet
- 1 IRSA, département Synergies, 37521 La Riche cedex, France
| |
Collapse
|
16
|
Gusto G, Vol S, Bedouet M, Leglu C, Decou P, Beslin É, Guillaud C, Copin N, Lantieri O, Tichet J. Reproductibilité et validation satisfaisantes d’un auto-questionnaire pour évaluer l’atteinte des repères du Programme National Nutrition Santé. Presse Med 2013; 42:e245-58. [DOI: 10.1016/j.lpm.2013.01.051] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2012] [Revised: 01/07/2013] [Accepted: 01/16/2013] [Indexed: 10/27/2022] Open
|
17
|
Mellerio H, Alberti C, Druet C, Capelier F, Mercat I, Josserand E, Vol S, Tichet J, Lévy-Marchal C. Novel modeling of reference values of cardiovascular risk factors in children aged 7 to 20 years. Pediatrics 2012; 129:e1020-9. [PMID: 22451707 DOI: 10.1542/peds.2011-0449] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Most of the cardiovascular risk factors strongly associated with obesity and overweight vary with age and gender. However, few reference values are available for healthy European children. Our objective was to establish pediatric reference ranges for waist circumference, systolic and diastolic blood pressures, fasting lipid levels (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides), glucose, and insulin. METHODS A representative sample of 1976 healthy French individuals (1004 female participants and 972 male participants) aged 7 to 20 years was used to obtain age- and gender-specific normal ranges for each of the above-listed cardiovascular risk factors, based on the Royston and Wright method. RESULTS Mean waist circumference increased with age in both genders and was slightly higher in males than in females. Whereas systolic blood pressure increased gradually with age, with the increase being steeper in males than in females, no gender effect was found for diastolic blood pressure, which was therefore modeled after pooling males and females. Total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride values varied little with age and gender. Glucose and insulin levels revealed pubertal peaks, which were sharper in females than in males, reflecting the normal insulin resistance during puberty. CONCLUSIONS These ranges can be used as references for European children to monitor cardiovascular risk factors and to plan interventions and education programs.
Collapse
Affiliation(s)
- Hélène Mellerio
- Inserm, Centre d’Investigation Clinique-Epidémiologie Clinique, CIE 5, Hôpital Robert Debré, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Palmer ND, McDonough CW, Hicks PJ, Roh BH, Wing MR, An SS, Hester JM, Cooke JN, Bostrom MA, Rudock ME, Talbert ME, Lewis JP, Ferrara A, Lu L, Ziegler JT, Sale MM, Divers J, Shriner D, Adeyemo A, Rotimi CN, Ng MCY, Langefeld CD, Freedman BI, Bowden DW, Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, Raychaudhuri S, McCarroll SA, Langenberg C, Hofmann OM, Dupuis J, Qi L, Segrè AV, van Hoek M, Navarro P, Ardlie K, Balkau B, Benediktsson R, Bennett AJ, Blagieva R, Boerwinkle E, Bonnycastle LL, Boström KB, Bravenboer B, Bumpstead S, Burtt NP, Charpentier G, Chines PS, Cornelis M, Couper DJ, Crawford G, Doney ASF, Elliott KS, Elliott AL, Erdos MR, Fox CS, Franklin CS, Ganser M, Gieger C, Grarup N, Green T, Griffin S, Groves CJ, Guiducci C, Hadjadj S, Hassanali N, Herder C, Isomaa B, Jackson AU, Johnson PRV, Jørgensen T, Kao WHL, Klopp N, Kong A, Kraft P, Kuusisto J, Lauritzen T, Li M, Lieverse A, Lindgren CM, Lyssenko V, Marre M, Meitinger T, Midthjell K, Morken MA, Narisu N, Nilsson P, Owen KR, Payne F, Perry JRB, Petersen AK, Platou C, Proença C, Prokopenko I, Rathmann W, Rayner NW, Robertson NR, Rocheleau G, Roden M, Sampson MJ, Saxena R, Shields BM, Shrader P, Sigurdsson G, Sparsø T, Strassburger K, Stringham HM, Sun Q, Swift AJ, Thorand B, Tichet J, Tuomi T, van Dam RM, van Haeften TW, van Herpt T, van Vliet-Ostaptchouk JV, Walters GB, Weedon MN, Wijmenga C, Witteman J, Bergman RN, Cauchi S, Collins FS, Gloyn AL, Gyllensten U, Hansen T, Hide WA, Hitman GA, Hofman A, Hunter DJ, Hveem K, Laakso M, Mohlke KL, Morris AD, Palmer CNA, Pramstaller PP, Rudan I, Sijbrands E, Stein LD, Tuomilehto J, Uitterlinden A, Walker M, Wareham NJ, Watanabe RM, Abecasis GR, Boehm BO, Campbell H, Daly MJ, Hattersley AT, Hu FB, Meigs JB, Pankow JS, Pedersen O, Wichmann HE, Barroso I, Florez JC, Frayling TM, Groop L, Sladek R, Thorsteinsdottir U, Wilson JF, Illig T, Froguel P, van Duijn CM, Stefansson K, Altshuler D, Boehnke M, McCarthy MI, Soranzo N, Wheeler E, Glazer NL, Bouatia-Naji N, Mägi R, Randall J, Johnson T, Elliott P, Rybin D, Henneman P, Dehghan A, Hottenga JJ, Song K, Goel A, Egan JM, Lajunen T, Doney A, Kanoni S, Cavalcanti-Proença C, Kumari M, Timpson NJ, Zabena C, Ingelsson E, An P, O'Connell J, Luan J, Elliott A, McCarroll SA, Roccasecca RM, Pattou F, Sethupathy P, Ariyurek Y, Barter P, Beilby JP, Ben-Shlomo Y, Bergmann S, Bochud M, Bonnefond A, Borch-Johnsen K, Böttcher Y, Brunner E, Bumpstead SJ, Chen YDI, Chines P, Clarke R, Coin LJM, Cooper MN, Crisponi L, Day INM, de Geus EJC, Delplanque J, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Grundy S, Gwilliam R, Hallmans G, Hammond N, Han X, Hartikainen AL, Hayward C, Heath SC, Hercberg S, Hicks AA, Hillman DR, Hingorani AD, Hui J, Hung J, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, Lecoeur C, Li Y, Mahley R, Mangino M, Manning AK, Martínez-Larrad MT, McAteer JB, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Mukherjee S, Naitza S, Neville MJ, Oostra BA, Orrù M, Pakyz R, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AFH, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Seedorf U, Sharp SJ, Shields B, Sijbrands EJG, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, Syvänen AC, Tanaka T, Tönjes A, Uitterlinden AG, van Dijk KW, Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Ward KL, Watkins H, Wild SH, Willemsen G, Witteman JCM, Yarnell JWG, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC, Borecki IB, Loos RJF, Meneton P, Magnusson PKE, Nathan DM, Williams GH, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Ríos M, Lind L, Palmer LJ, Franks PW, Ebrahim S, Marmot M, Kao WHL, Pramstaller PP, Wright AF, Stumvoll M, Hamsten A, Buchanan TA, Valle TT, Rotter JI, Siscovick DS, Penninx BWJH, Boomsma DI, Deloukas P, Spector TD, Ferrucci L, Cao A, Scuteri A, Schlessinger D, Uda M, Ruokonen A, Jarvelin MR, Waterworth DM, Vollenweider P, Peltonen L, Mooser V, Sladek R. A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One 2012; 7:e29202. [PMID: 22238593 PMCID: PMC3251563 DOI: 10.1371/journal.pone.0029202] [Citation(s) in RCA: 137] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2011] [Accepted: 11/22/2011] [Indexed: 12/16/2022] Open
Abstract
African Americans are disproportionately affected by type 2 diabetes (T2DM) yet few studies have examined T2DM using genome-wide association approaches in this ethnicity. The aim of this study was to identify genes associated with T2DM in the African American population. We performed a Genome Wide Association Study (GWAS) using the Affymetrix 6.0 array in 965 African-American cases with T2DM and end-stage renal disease (T2DM-ESRD) and 1029 population-based controls. The most significant SNPs (n = 550 independent loci) were genotyped in a replication cohort and 122 SNPs (n = 98 independent loci) were further tested through genotyping three additional validation cohorts followed by meta-analysis in all five cohorts totaling 3,132 cases and 3,317 controls. Twelve SNPs had evidence of association in the GWAS (P<0.0071), were directionally consistent in the Replication cohort and were associated with T2DM in subjects without nephropathy (P<0.05). Meta-analysis in all cases and controls revealed a single SNP reaching genome-wide significance (P<2.5×10(-8)). SNP rs7560163 (P = 7.0×10(-9), OR (95% CI) = 0.75 (0.67-0.84)) is located intergenically between RND3 and RBM43. Four additional loci (rs7542900, rs4659485, rs2722769 and rs7107217) were associated with T2DM (P<0.05) and reached more nominal levels of significance (P<2.5×10(-5)) in the overall analysis and may represent novel loci that contribute to T2DM. We have identified novel T2DM-susceptibility variants in the African-American population. Notably, T2DM risk was associated with the major allele and implies an interesting genetic architecture in this population. These results suggest that multiple loci underlie T2DM susceptibility in the African-American population and that these loci are distinct from those identified in other ethnic populations.
Collapse
Affiliation(s)
- Nicholette D Palmer
- Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Salvi E, Kutalik Z, Glorioso N, Benaglio P, Frau F, Kuznetsova T, Arima H, Hoggart C, Tichet J, Nikitin YP, Conti C, Seidlerova J, Tikhonoff V, Stolarz-Skrzypek K, Johnson T, Devos N, Zagato L, Guarrera S, Zaninello R, Calabria A, Stancanelli B, Troffa C, Thijs L, Rizzi F, Simonova G, Lupoli S, Argiolas G, Braga D, D'Alessio MC, Ortu MF, Ricceri F, Mercurio M, Descombes P, Marconi M, Chalmers J, Harrap S, Filipovsky J, Bochud M, Iacoviello L, Ellis J, Stanton AV, Laan M, Padmanabhan S, Dominiczak AF, Samani NJ, Melander O, Jeunemaitre X, Manunta P, Shabo A, Vineis P, Cappuccio FP, Caulfield MJ, Matullo G, Rivolta C, Munroe PB, Barlassina C, Staessen JA, Beckmann JS, Cusi D. Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension 2011; 59:248-55. [PMID: 22184326 DOI: 10.1161/hypertensionaha.111.181990] [Citation(s) in RCA: 120] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Essential hypertension is a multifactorial disorder and is the main risk factor for renal and cardiovascular complications. The research on the genetics of hypertension has been frustrated by the small predictive value of the discovered genetic variants. The HYPERGENES Project investigated associations between genetic variants and essential hypertension pursuing a 2-stage study by recruiting cases and controls from extensively characterized cohorts recruited over many years in different European regions. The discovery phase consisted of 1865 cases and 1750 controls genotyped with 1M Illumina array. Best hits were followed up in a validation panel of 1385 cases and 1246 controls that were genotyped with a custom array of 14 055 markers. We identified a new hypertension susceptibility locus (rs3918226) in the promoter region of the endothelial NO synthase gene (odds ratio: 1.54 [95% CI: 1.37-1.73]; combined P=2.58 · 10(-13)). A meta-analysis, using other in silico/de novo genotyping data for a total of 21 714 subjects, resulted in an overall odds ratio of 1.34 (95% CI: 1.25-1.44; P=1.032 · 10(-14)). The quantitative analysis on a population-based sample revealed an effect size of 1.91 (95% CI: 0.16-3.66) for systolic and 1.40 (95% CI: 0.25-2.55) for diastolic blood pressure. We identified in silico a potential binding site for ETS transcription factors directly next to rs3918226, suggesting a potential modulation of endothelial NO synthase expression. Biological evidence links endothelial NO synthase with hypertension, because it is a critical mediator of cardiovascular homeostasis and blood pressure control via vascular tone regulation. This finding supports the hypothesis that there may be a causal genetic variation at this locus.
Collapse
Affiliation(s)
- Erika Salvi
- Department of Medicine, Surgery, and Dentistry, Graduate School of Nephrology, University of Milano, Division of Nephrology, San Paolo Hospital, Milano, Viale Ortles 22/4, 20139 Milano, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Johnson T, Gaunt T, Newhouse S, Padmanabhan S, Tomaszewski M, Kumari M, Morris R, Tzoulaki I, O'Brien E, Poulter N, Sever P, Shields D, Thom S, Wannamethee S, Whincup P, Brown M, Connell J, Dobson R, Howard P, Mein C, Onipinla A, Shaw-Hawkins S, Zhang Y, Smith G, Day I, Lawlor D, Goodall A, Fowkes F, Abecasis G, Elliott P, Gateva V, Braund P, Burton P, Nelson C, Tobin M, van der Harst P, Glorioso N, Neuvrith H, Salvi E, Staessen J, Stucchi A, Devos N, Jeunemaitre X, Plouin PF, Tichet J, Juhanson P, Org E, Putku M, Sõber S, Veldre G, Viigimaa M, Levinsson A, Rosengren A, Thelle D, Hastie C, Hedner T, Lee W, Melander O, Wahlstrand B, Hardy R, Wong A, Cooper J, Palmen J, Chen L, Stewart A, Wells G, Westra HJ, Wolfs M, Clarke R, Franzosi M, Goel A, Hamsten A, Lathrop M, Peden J, Seedorf U, Watkins H, Ouwehand W, Sambrook J, Stephens J, Casas JP, Drenos F, Holmes M, Kivimaki M, Shah S, Shah T, Talmud P, Whittaker J, Wallace C, Delles C, Laan M, Kuh D, Humphries S, Nyberg F, Cusi D, Roberts R, Newton-Cheh C, Franke L, Stanton A, Dominiczak A, Farrall M, Hingorani A, Samani N, Caulfield M, Munroe P, Caulfield MJ, Munroe PB. Blood pressure loci identified with a gene-centric array. Am J Hum Genet 2011; 89:688-700. [PMID: 22100073 DOI: 10.1016/j.ajhg.2011.10.013] [Citation(s) in RCA: 132] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2011] [Revised: 09/21/2011] [Accepted: 10/27/2011] [Indexed: 12/15/2022] Open
Abstract
Raised blood pressure (BP) is a major risk factor for cardiovascular disease. Previous studies have identified 47 distinct genetic variants robustly associated with BP, but collectively these explain only a few percent of the heritability for BP phenotypes. To find additional BP loci, we used a bespoke gene-centric array to genotype an independent discovery sample of 25,118 individuals that combined hypertensive case-control and general population samples. We followed up four SNPs associated with BP at our p < 8.56 × 10(-7) study-specific significance threshold and six suggestively associated SNPs in a further 59,349 individuals. We identified and replicated a SNP at LSP1/TNNT3, a SNP at MTHFR-NPPB independent (r(2) = 0.33) of previous reports, and replicated SNPs at AGT and ATP2B1 reported previously. An analysis of combined discovery and follow-up data identified SNPs significantly associated with BP at p < 8.56 × 10(-7) at four further loci (NPR3, HFE, NOS3, and SOX6). The high number of discoveries made with modest genotyping effort can be attributed to using a large-scale yet targeted genotyping array and to the development of a weighting scheme that maximized power when meta-analyzing results from samples ascertained with extreme phenotypes, in combination with results from nonascertained or population samples. Chromatin immunoprecipitation and transcript expression data highlight potential gene regulatory mechanisms at the MTHFR and NOS3 loci. These results provide candidates for further study to help dissect mechanisms affecting BP and highlight the utility of studying SNPs and samples that are independent of those studied previously even when the sample size is smaller than that in previous studies.
Collapse
|
21
|
Vol S, Bedouet M, Gusto G, Leglu C, Beslin E, Decou P, Nègre E, Planage B, Chazelle E, Mercier F, Lantieri O, Tichet J. Evaluating physical activity: The AQAP questionnaire and its interpretation software. Ann Phys Rehabil Med 2011; 54:478-95. [DOI: 10.1016/j.rehab.2011.09.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2010] [Revised: 09/06/2011] [Accepted: 09/08/2011] [Indexed: 12/01/2022]
|
22
|
Alberti C, Chevenne D, Mercat I, Josserand E, Armoogum-Boizeau P, Tichet J, Léger J. Serum Concentrations of Insulin-like Growth Factor (IGF)-1 and IGF Binding Protein-3 (IGFBP-3), IGF-1/IGFBP-3 Ratio, and Markers of Bone Turnover: Reference Values for French Children and Adolescents and z-Score Comparability with Other References. Clin Chem 2011; 57:1424-35. [DOI: 10.1373/clinchem.2011.169466] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND
A reference model for converting serum growth factor and bone metabolism markers into an SD score (SDS) is required for clinical practice. We aimed to establish reference values of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein 3 (IGFBP-3) concentrations and bone metabolism markers in French children, to generate a model for converting values into SDS for age, sex, and pubertal stage.
METHODS
We carried out a cross-sectional study of 1119 healthy white children ages 6–20 years. We assessed concentrations of serum IGF-1, IGFBP-3, carboxyterminal telopeptide α1 chain of type I collagen (CrossLaps), and bone alkaline phosphatase concentrations and height, weight, and pubertal stage, and used semiparametric regression to develop a model.
RESULTS
A single regression model to calculate the SDSs with an online calculator was provided. A positive relationship was found between SDS for serum IGF-1 and IGFBP-3, IGF/IGFBP-3 mol/L ratio, and anthropometric parameters (P < 0.0001), with slightly greater effects observed for height than for body mass index (BMI). There was a negative relationship between serum CrossLaps concentration and BMI, and a positive relationship between serum CrossLaps concentration and height. A comparison of serum IGF-1 reference databases for children showed marked variation as a function of age and pubertal group; smooth changes with age and puberty were observed only in our model.
CONCLUSIONS
This new model for the assessment of SDS reference values specific for age, sex, and pubertal stage may help to increase the diagnostic power of these parameters for the assessment of growth and bone metabolism disorders. This study also provides information about the physiological role of height and BMI for the interpretation of these parameters.
Collapse
Affiliation(s)
- Corinne Alberti
- INSERM, CIC-EC CIE5, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Unité d'Epidémiologie Clinique, Paris, France
- Université Paris Diderot, Paris, France
| | - Didier Chevenne
- Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Service de Biochimie-Hormonologie, Paris, France
| | | | - Emilie Josserand
- Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Unité d'Epidémiologie Clinique, Paris, France
| | - Priscilla Armoogum-Boizeau
- Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Unité d'Epidémiologie Clinique, Paris, France
| | - Jean Tichet
- Regional Institute for Health, Tours, France
| | - Juliane Léger
- Université Paris Diderot, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Service d'Endocrinologie Pédiatrique, Paris, France
- Assistance Publique-Hôpitaux de Paris, Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, France
- INSERM, UMR 676, Paris, France
| |
Collapse
|
23
|
Guittet L, Guillaume E, Levillain R, Beley P, Tichet J, Lantieri O, Launoy G. Analytical Comparison of Three Quantitative Immunochemical Fecal Occult Blood Tests for Colorectal Cancer Screening. Cancer Epidemiol Biomarkers Prev 2011; 20:1492-501. [DOI: 10.1158/1055-9965.epi-10-0594] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
24
|
Balkau B, Soulimane S, Lange C, Gautier A, Tichet J, Vol S. Are the same clinical risk factors relevant for incident diabetes defined by treatment, fasting plasma glucose, and HbA1c? Diabetes Care 2011; 34:957-9. [PMID: 21346181 PMCID: PMC3064057 DOI: 10.2337/dc10-1581] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To compare incidences and risk factors for diabetes using seven definitions, with combinations of pharmacological treatment, fasting plasma glucose (FPG) ≥7.0 mmol/L, and HbA(1c) ≥6.5%. RESEARCH DESIGN AND METHODS Participants aged 30-65 years from the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort were followed for 9 years. RESULTS More men had incident diabetes as defined by FPG ≥7.0 mmol/L and/or treatment than by HbA(1c) ≥6.5% and/or treatment: 7.5% (140/1,867) and 5.3% (99/1,874), respectively (P < 0.009); for women incidences were similar: 3.2% (63/1,958) and 3.4% (66/1,954). Known risk factors predicted diabetes for almost all definitions. Among those with incident diabetes by FPG alone versus HbA(1c) alone, there were more men (78 vs. 35%), case patients were 8 years younger, and fewer were alcohol abstainers (12 vs. 35%) (all P < 0.005). A diabetes risk score discriminated well between those with and without incident diabetes for all definitions. CONCLUSIONS In men, FPG definitions yielded more incident cases of diabetes than HbA(1c) definitions, in contrast with women. An FPG-derived risk score remained relevant for HbA(1c)-defined diabetes.
Collapse
Affiliation(s)
- Beverley Balkau
- INSERM, CESP Center for Research in Epidemiology and Population Health, Epidemiology of Diabetes, Obesity and Chronic Kidney Disease Over the Lifecourse, U1018, Villejuif, France.
| | | | | | | | | | | | | |
Collapse
|
25
|
Valensi P, Extramiana F, Lange C, Cailleau M, Haggui A, Maison Blanche P, Tichet J, Balkau B. Influence of blood glucose on heart rate and cardiac autonomic function. The DESIR study. Diabet Med 2011; 28:440-9. [PMID: 21204961 DOI: 10.1111/j.1464-5491.2010.03222.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
OBJECTIVES To evaluate in a general population, the relationships between dysglycaemia, insulin resistance and metabolic variables, and heart rate, heart rate recovery and heart rate variability. METHODS Four hundred and forty-seven participants in the Data from an Epidemiological Study on the Insulin Resistance syndrome (DESIR) study were classified according to glycaemic status over the preceding 9 years. All were free of self-reported cardiac antecedents and were not taking drugs which alter heart rate. During five consecutive periods: rest, deep breathing, recovery, rest and lying to standing, heart rate and heart rate varability were evaluated and compared by ANCOVA and trend tests across glycaemic classes. Spearman correlation coefficients quantified the relations between cardio-metabolic risk factors, heart rate and heart rate varability. RESULTS Heart rate differed between glycaemic groups, except during deep breathing. Between rest and deep-breathing periods, patients with diabetes had a lower increase in heart rate than others (P(trend) < 0.01); between deep breathing and recovery, the heart rate of patients with diabetes continued to increase, for others, heart rate decreased (P(trend) < 0.009). Heart rate was correlated with capillary glucose and triglycerides during the five test periods. Heart rate variability differed according to glycaemic status, especially during the recovery period. After age, sex and BMI adjustment, heart rate variability was correlated with triglycerides at two test periods. Change in heart rate between recovery and deep breathing was negatively correlated with heart rate variability at rest, (r=-0.113, P < 0.05): lower resting heart rate variability was associated with heart rate acceleration. CONCLUSIONS Heart rate, but not heart rate variability, was associated with glycaemic status and capillary glucose. After deep breathing, heart rate recovery was altered in patients with known diabetes and was associated with reduced heart rate variability. Being overweight was a major correlate of heart rate variability.
Collapse
Affiliation(s)
- P Valensi
- Department of Endocrinology-Diabetology-Nutrition, Paris-Nord University, Jean Verdier Hospital, Bondy, France
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, Raychaudhuri S, McCarroll SA, Langenberg C, Hofmann OM, Dupuis J, Qi L, Segrè AV, van Hoek M, Navarro P, Ardlie K, Balkau B, Benediktsson R, Bennett AJ, Blagieva R, Boerwinkle E, Bonnycastle LL, Boström KB, Bravenboer B, Bumpstead S, Burtt NP, Charpentier G, Chines PS, Cornelis M, Couper DJ, Crawford G, Doney ASF, Elliott KS, Elliott AL, Erdos MR, Fox CS, Franklin CS, Ganser M, Gieger C, Grarup N, Green T, Griffin S, Groves CJ, Guiducci C, Hadjadj S, Hassanali N, Herder C, Isomaa B, Jackson AU, Johnson PRV, Jørgensen T, Kao WHL, Klopp N, Kong A, Kraft P, Kuusisto J, Lauritzen T, Li M, Lieverse A, Lindgren CM, Lyssenko V, Marre M, Meitinger T, Midthjell K, Morken MA, Narisu N, Nilsson P, Owen KR, Payne F, Perry JRB, Petersen AK, Platou C, Proença C, Prokopenko I, Rathmann W, Rayner NW, Robertson NR, Rocheleau G, Roden M, Sampson MJ, Saxena R, Shields BM, Shrader P, Sigurdsson G, Sparsø T, Strassburger K, Stringham HM, Sun Q, Swift AJ, Thorand B, Tichet J, Tuomi T, van Dam RM, van Haeften TW, van Herpt T, van Vliet-Ostaptchouk JV, Walters GB, Weedon MN, Wijmenga C, Witteman J, Bergman RN, Cauchi S, Collins FS, Gloyn AL, Gyllensten U, Hansen T, Hide WA, Hitman GA, Hofman A, Hunter DJ, Hveem K, Laakso M, Mohlke KL, Morris AD, Palmer CNA, Pramstaller PP, Rudan I, Sijbrands E, Stein LD, Tuomilehto J, Uitterlinden A, Walker M, Wareham NJ, Watanabe RM, Abecasis GR, Boehm BO, Campbell H, Daly MJ, Hattersley AT, Hu FB, Meigs JB, Pankow JS, Pedersen O, Wichmann HE, Barroso I, Florez JC, Frayling TM, Groop L, Sladek R, Thorsteinsdottir U, Wilson JF, Illig T, Froguel P, van Duijn CM, Stefansson K, Altshuler D, Boehnke M, McCarthy MI. Erratum: Corrigendum: Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2011. [DOI: 10.1038/ng0411-388b] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
27
|
Rouvre M, Vol S, Gusto G, Born C, Lantieri O, Tichet J, Lecomte P. Low high density lipoprotein cholesterol: prevalence and associated risk-factors in a large French population. Ann Epidemiol 2011; 21:118-27. [PMID: 21184952 DOI: 10.1016/j.annepidem.2010.07.097] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2010] [Revised: 07/07/2010] [Accepted: 07/22/2010] [Indexed: 11/27/2022]
Abstract
PURPOSE High density lipoprotein-cholesterol (HDL-C) is a strong predictor of cardiovascular risk. We investigated the distribution of HDL-C in a French general population according to age, sex, and the risk factors associated with low HDL-C values. METHODS A group of 18,483 men and 22,047 women 16-79 years of age were investigated during a medical check-up. Relevant parameters were studied in three groups according to age and gender-specific percentile classes (≤5th [HDL₅] median and >95th). Gender-specific logistic regression models selected variables associated with HDL₅. RESULTS Using the National Cholesterol Education Program Adult Treatment Panel III criteria (threshold: 40 mg/dL in men, 50 mg/dL in women) the prevalence of low HDL-C was 11.1% and 26.4% in men and women and it decreased with age. Mean HDL-C levels increased with age. HDL₅ was positively associated with a sedentary lifestyle and deprivation (p < 0.00001) even after adjustment on alcohol consumption and smoking. Abdominal obesity, smoking, hypertriglyceridemia, hyperleucocytosis, and low alcohol consumption were associated with HDL₅ for both genders. CONCLUSIONS The prevalence of low HDL-C was similar to that observed in other Europeans but lower than in the United States. HDL₅ was associated with cardiovascular risk factors, metabolic syndrome, and social deprivation. A prevention policy to increase HDL-C levels should focus on reducing smoking and abdominal obesity, particularly in deprived subjects.
Collapse
Affiliation(s)
- Marion Rouvre
- Centre Hospitalier Régional et Universitaire Bretonneau, Tours, France
| | | | | | | | | | | | | |
Collapse
|
28
|
Massin P, Lange C, Tichet J, Vol S, Erginay A, Cailleau M, Eschwège E, Balkau B. Hemoglobin A1c and fasting plasma glucose levels as predictors of retinopathy at 10 years: the French DESIR study. ACTA ACUST UNITED AC 2011; 129:188-95. [PMID: 21320965 DOI: 10.1001/archophthalmol.2010.353] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
OBJECTIVE To evaluate the predictive values of hemoglobin A(1c) (HbA(1c)) and fasting plasma glucose (FPG) for retinopathy 10 years after the baseline examination. METHODS Seven hundred men and women from the DESIR (Data From an Epidemiological Study on the Insulin Resistance Syndrome) Study underwent evaluation for retinopathy using a nonmydriatic digital camera. During the preceding 9 years, 235 had diabetes mellitus (treated or FPG level of ≥126 mg/dL at least once), 227 had an impaired FPG level (110-125 mg/dL) at least once, and 238 always had glucose levels within reference limits (<110 mg/dL). RESULTS Compared with those without retinopathy, the 44 participants with retinopathy at 10 years had higher baseline mean (SD) levels of FPG (130 [49] vs 106 [22] mg/dL) and HbA(1c) (6.4% [1.6%] vs 5.7% [0.7%]) (both, P < .001). The frequency of retinopathy at 10 years, standardized according to the distribution of glycemia across the entire DESIR population, was 3.6%. In our population, FPG levels of 108 and 116 mg/dL had positive predictive values of 8.4% and 14.0%, respectively, for retinopathy at 10 years; HbA(1c) levels of 6.0% and 6.5% had positive predictive values of 6.0% and 14.8%, respectively. After 10 years of follow-up, retinopathy was equally frequent in participants with impaired FPG levels and in those who became diabetic during the study (8.6% and 6.7%, respectively), lower than in those with diabetes at baseline (13.9%). CONCLUSION Because the positive predictive values for retinopathy increase sharply from 108 mg/dL for FPG and from 6.0% for HbA(1c) levels, these thresholds are proposed to identify those at risk of retinopathy 10 years later.
Collapse
Affiliation(s)
- Pascale Massin
- Ophthalmology Department, Assistance Publique Hôpitaux de Paris, Hôpital Lariboisière, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Cheurfa N, Brenner GM, Reis AF, Dubois-Laforgue D, Roussel R, Tichet J, Lantieri O, Balkau B, Fumeron F, Timsit J, Marre M, Velho G. Decreased insulin secretion and increased risk of type 2 diabetes associated with allelic variations of the WFS1 gene: the Data from Epidemiological Study on the Insulin Resistance Syndrome (DESIR) prospective study. Diabetologia 2011; 54:554-62. [PMID: 21127832 DOI: 10.1007/s00125-010-1989-0] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2010] [Accepted: 10/22/2010] [Indexed: 12/01/2022]
Abstract
AIMS/HYPOTHESIS We investigated associations of allelic variations in the WFS1 gene with insulin secretion and risk of type 2 diabetes in a general population prospective study. METHODS We studied 5,110 unrelated French men and women who participated in the prospective Data from Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Additional cross-sectional analyses were performed on 4,472 French individuals with type 2 diabetes and 3,065 controls. Three single nucleotide polymorphisms (SNPs) were genotyped: rs10010131, rs1801213/rs7672995 and rs734312. RESULTS We observed statistically significant associations between the major alleles of the three variants and prevalent type 2 diabetes in the DESIR cohort at baseline. Cox analyses showed an association between the G-allele of rs10010131 and incident type 2 diabetes (HR 1.34, 95% CI 1.08-1.70, p = 0.007). Similar results were observed for the G-allele of rs1801213 and the A-allele of rs734312. The GGA haplotype was associated with an increased risk of diabetes as compared with the ACG haplotype (HR 1.26, 95% CI 1.04-1.42, p = 0.02). We also observed statistically significant associations of the three SNPs with plasma glucose, HbA(1c) levels and insulin secretion at baseline and throughout the study in individuals with type 2 diabetes or at risk of developing diabetes. However, no association was observed in those who remained normoglycaemic at the end of the follow-up. Associations between the three variants and type 2 diabetes were replicated in cross-sectional studies of type 2 diabetic patients in comparison with a non-diabetic control group. CONCLUSIONS/INTERPRETATION The most frequent haplotype at the haplotype block containing the WFS1 gene modulated insulin secretion and was associated with an increased risk of type 2 diabetes.
Collapse
Affiliation(s)
- N Cheurfa
- INSERM, Research Unit 695, 16 rue Henri Huchard, 75018, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Safar ME, Lange C, Blacher J, Eschwège E, Tichet J, Balkau B. Mean and yearly changes in blood pressure with age in the metabolic syndrome: the DESIR study. Hypertens Res 2010; 34:91-7. [PMID: 20927113 DOI: 10.1038/hr.2010.180] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Systolic and diastolic blood pressure (SBP; DBP) increase with age, but after 45 years of age, the yearly change in DBP (ΔDBP) tends to be smaller in comparison with the yearly change in SBP (ΔSBP), which increases with age. The effect of the metabolic syndrome (MetS) on this yearly change has never been explored. In a 9-year longitudinal cohort Data from an Epidemiologic Study on the Insulin Resistance syndrome (DESIR) study, we examined 1308 men and 1325 women, aged 30-65 years, who had never been treated for hypertension. SBP and DBP were measured at four examinations 3 years apart, and pulse pressure (PP) and yearly changes (ΔSBP, ΔDBP and ΔPP) were calculated. SBP and PP increased with age to a higher degree in patients with the MetS. In men and women with the MetS, DBP remained nearly constant, but in those without the MetS, DBP increased. After adjusting for baseline values, ΔSBP and ΔPP increased by 0.5 mm Hg per year for every additional 10 years from baseline. These correlations with age were similar for men and women, and the yearly change was always higher than in those with the MetS. In contrast, ΔDBP increased very slowly until 50 years of age and then decreased similarly for those with and without the MetS. The increase in PP with age, a marker of vascular aging, was determined to begin earlier in the present study than has been shown in the past, and the MetS amplified this effect. This new aspect of the MetS might modify clinical management leading to earlier drug treatment, particularly in regard to both endothelial dysfunction and increased arterial stiffness.
Collapse
|
31
|
Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, Raychaudhuri S, McCarroll SA, Langenberg C, Hofmann OM, Dupuis J, Qi L, Segrè AV, van Hoek M, Navarro P, Ardlie K, Balkau B, Benediktsson R, Bennett AJ, Blagieva R, Boerwinkle E, Bonnycastle LL, Bengtsson Boström K, Bravenboer B, Bumpstead S, Burtt NP, Charpentier G, Chines PS, Cornelis M, Couper DJ, Crawford G, Doney ASF, Elliott KS, Elliott AL, Erdos MR, Fox CS, Franklin CS, Ganser M, Gieger C, Grarup N, Green T, Griffin S, Groves CJ, Guiducci C, Hadjadj S, Hassanali N, Herder C, Isomaa B, Jackson AU, Johnson PRV, Jørgensen T, Kao WHL, Klopp N, Kong A, Kraft P, Kuusisto J, Lauritzen T, Li M, Lieverse A, Lindgren CM, Lyssenko V, Marre M, Meitinger T, Midthjell K, Morken MA, Narisu N, Nilsson P, Owen KR, Payne F, Perry JRB, Petersen AK, Platou C, Proença C, Prokopenko I, Rathmann W, Rayner NW, Robertson NR, Rocheleau G, Roden M, Sampson MJ, Saxena R, Shields BM, Shrader P, Sigurdsson G, Sparsø T, Strassburger K, Stringham HM, Sun Q, Swift AJ, Thorand B, Tichet J, Tuomi T, van Dam RM, van Haeften TW, van Herpt T, van Vliet-Ostaptchouk JV, Walters GB, Weedon MN, Wijmenga C, Witteman J, Bergman RN, Cauchi S, Collins FS, Gloyn AL, Gyllensten U, Hansen T, Hide WA, Hitman GA, Hofman A, Hunter DJ, Hveem K, Laakso M, Mohlke KL, Morris AD, Palmer CNA, Pramstaller PP, Rudan I, Sijbrands E, Stein LD, Tuomilehto J, Uitterlinden A, Walker M, Wareham NJ, Watanabe RM, Abecasis GR, Boehm BO, Campbell H, Daly MJ, Hattersley AT, Hu FB, Meigs JB, Pankow JS, Pedersen O, Wichmann HE, Barroso I, Florez JC, Frayling TM, Groop L, Sladek R, Thorsteinsdottir U, Wilson JF, Illig T, Froguel P, van Duijn CM, Stefansson K, Altshuler D, Boehnke M, McCarthy MI. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42:579-89. [PMID: 20581827 DOI: 10.1038/ng.609] [Citation(s) in RCA: 1338] [Impact Index Per Article: 95.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2010] [Accepted: 05/26/2010] [Indexed: 12/11/2022]
Abstract
By combining genome-wide association data from 8,130 individuals with type 2 diabetes (T2D) and 38,987 controls of European descent and following up previously unidentified meta-analysis signals in a further 34,412 cases and 59,925 controls, we identified 12 new T2D association signals with combined P<5x10(-8). These include a second independent signal at the KCNQ1 locus; the first report, to our knowledge, of an X-chromosomal association (near DUSP9); and a further instance of overlap between loci implicated in monogenic and multifactorial forms of diabetes (at HNF1A). The identified loci affect both beta-cell function and insulin action, and, overall, T2D association signals show evidence of enrichment for genes involved in cell cycle regulation. We also show that a high proportion of T2D susceptibility loci harbor independent association signals influencing apparently unrelated complex traits.
Collapse
Affiliation(s)
- Benjamin F Voight
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Miot A, Maimaitiming S, Emery N, Bellili N, Roussel R, Tichet J, Velho G, Balkau B, Marre M, Fumeron F. Genetic variability at the six transmembrane protein of prostate 2 locus and the metabolic syndrome: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. J Clin Endocrinol Metab 2010; 95:2942-7. [PMID: 20382686 DOI: 10.1210/jc.2010-0026] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
CONTEXT The six-transmembrane protein of prostate 2 (STAMP2) has been shown to be involved in insulin resistance in animal models, but in humans, its role is far from understood. Our hypothesis was that genetic variation of STAMP2 could be associated with insulin resistance phenotypes such as the metabolic syndrome (MetS) in humans. OBJECTIVE Our objective was to search for associations between STAMP2 polymorphisms and the MetS in humans. SUBJECTS AND METHODS Nine single-nucleotide polymorphisms (SNPs) were tested for associations with the International Diabetes Federation-defined MetS and its constituent parameters in 5212 French Caucasians from the prospective study, Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR), with a 9-yr follow-up. Methods included logistic regression and analysis of covariance adjusting for confounding variables and testing for interactions. RESULTS None of the SNPs was significantly associated with the prevalence or the incidence of the MetS. The rs12386756 was marginally associated with two parameters of the MetS [triglycerides (P = 0.04) and fasting glucose (P = 0.05)]. An interaction effect between this SNP and fat intake was observed on high-density lipoprotein-cholesterol levels (P = 0.01) and systolic blood pressure (P = 0.03) that is consistent with an interrelation between STAMP2 and nutrition. Three SNPs were associated with insulin levels, but these SNPs were not associated with other features of the MetS. CONCLUSION These findings suggest that the common polymorphisms of STAMP2 are unlikely to significantly contribute to the risk of the MetS in the general population, but relationships with insulin and interactions with fat intake need to be replicated.
Collapse
Affiliation(s)
- Aurélie Miot
- Institut National de la Santé et de la Recherche Médicale Unité 695, Xavier Bichat School of Medicine, 75870 Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Bellili NM, Foucan L, Fumeron F, Mohammedi K, Travert F, Roussel R, Balkau B, Tichet J, Marre M. Associations of the -344 T>C and the 3097 G>A polymorphisms of CYP11B2 gene with hypertension, type 2 diabetes, and metabolic syndrome in a French population. Am J Hypertens 2010; 23:660-7. [PMID: 20224556 DOI: 10.1038/ajh.2010.44] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Aldosterone can affect both blood pressure (BP) and glucose metabolism. We assessed the association of two polymorphisms -344 T>C and the 3097 G>A in the aldosterone synthase gene (CYP11B2) with prevalent and incident hypertension (HT), type 2 diabetes (T2D), and the metabolic syndrome (MetS). METHODS We studied the 5,212 participants to D.E.S.I.R. (Data from Epidemiologic Study on the Insulin Resistance syndrome), a cohort from French general population. Genotyping was done by a TaqMan assay. Analysis of covariance, multivariate logistic regression (adjusted for age, MetS components) and haplotype analysis were performed. RESULTS The prevalences and 9-year incidences were 16.7 and 36.1% for HT, 2.6 and 6.2% for T2D, and 19.3 and 25.1% for the MetS. Risk for incident HT was reduced with the AA genotype of 3097 G>A, adjusted odds ratios (OR): 0.67; p = 0.04. The prevalence of HT was lower in women carrying the C allele of -344 T>C, OR 0.75; p = 0.03 for the TC genotype and 0.69; p = 0.03 for the CC genotype. In men, incident T2D was associated with both polymorphisms, adjusted OR for -344 T>C: 1.63; p = 0.04 for TC genotype and 2.12; p = 0.008 for CC genotype; for the 3097 G>A: the AA genotype was associated with a lower risk, OR 0.23; p = 0.02. In men, incident MetS was associated with 3097 G>A, OR: 0.57; p = 0.02 for AA genotype. Significant associations between haplotype combinations and the prevalence or incidence of the three diseases were also found. CONCLUSION The -344 T>C and 3097 G>A polymorphisms in the CYP11B2 are associated with T2D, hypertension and the MetS in European subjects with gender variations.
Collapse
|
34
|
Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Mägi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JRB, Egan JM, Lajunen T, Grarup N, Sparsø T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proença C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O'Connell J, Luan J, Elliott A, McCarroll SA, Payne F, Roccasecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, Beilby JP, Ben-Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Böttcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen YDI, Chines P, Clarke R, Coin LJM, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day INM, de Geus EJC, Delplanque J, Dina C, Erdos MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Groves CJ, Grundy S, Gwilliam R, Gyllensten U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen AL, Hassanali N, Hayward C, Heath SC, Hercberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa B, Johnson PRV, Jørgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, Lecoeur C, Li Y, Lyssenko V, Mahley R, Mangino M, Manning AK, Martínez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orrù M, Pakyz R, Palmer CNA, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AFH, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott LJ, Seedorf U, Sharp SJ, Shields B, SigurÐsson G, Sijbrands EJG, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, Syvänen AC, Tanaka T, Thorand B, Tichet J, Tönjes A, Tuomi T, Uitterlinden AG, van Dijk KW, van Hoek M, Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H, Weedon MN, Wild SH, Willemsen G, Witteman JCM, Yarnell JWG, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC, Consortium DIAGRAM, Consortium GIANT, Consortium GBP, Borecki IB, Loos RJF, Meneton P, Magnusson PKE, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Ríos M, Morris AD, Lind L, Palmer LJ, Hu FB, Franks PW, Ebrahim S, Marmot M, Kao WHL, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T, Pedersen O, Pramstaller PP, Wichmann HE, Illig T, Rudan I, Wright AF, Stumvoll M, Campbell H, Wilson JF, Hamsten A, Bergman RN, Buchanan TA, Collins FS, Mohlke KL, Tuomilehto J, Valle TT, Altshuler D, Rotter JI, Siscovick DS, Penninx BWJH, Boomsma DI, Deloukas P, Spector TD, Frayling TM, Ferrucci L, Kong A, Thorsteinsdottir U, Stefansson K, van Duijn CM, Aulchenko YS, Cao A, Scuteri A, Schlessinger D, Uda M, Ruokonen A, Jarvelin MR, Waterworth DM, Vollenweider P, Peltonen L, Mooser V, Abecasis GR, Wareham NJ, Sladek R, Froguel P, Watanabe RM, Meigs JB, Groop L, Boehnke M, McCarthy MI, Florez JC, Barroso I. Erratum: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010. [DOI: 10.1038/ng0510-464a] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
35
|
Balkau B, Vol S, Loko S, Andriamboavonjy T, Lantieri O, Gusto G, Meslier N, Racineux JL, Tichet J. High baseline insulin levels associated with 6-year incident observed sleep apnea. Diabetes Care 2010; 33:1044-9. [PMID: 20185739 PMCID: PMC2858172 DOI: 10.2337/dc09-1901] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Obstructive sleep apnea is common in patients with type 2 diabetes, and its association with insulin and insulin resistance has been examined in cross-sectional studies. We evaluate risk factors for incident observed sleep apnea in a general population not selected for sleep disturbances. RESEARCH DESIGN AND METHODS A total of 1,780 men and 1,785 women, aged 33 to 68 years, from the cohort Data from an Epidemiologic Study on the Insulin Resistance Syndrome (D.E.S.I.R.) responded to the question, "Has someone said to you that you stop breathing during your sleep?" at baseline and 6 years. Anthropometric, clinical, and biological factors were recorded at both time points. RESULTS At baseline, 14% of men and 7% of women reported having observed sleep apnea (positive response to question); 6-year incidences were 14 and 6%, respectively. Age, anthropometric parameters, blood pressure, and sleep characteristics were all associated with prevalent, observed apnea episodes, in both sexes. Baseline waist circumference was the strongest predictor of incident apnea: standardized odds ratio (OR), adjusted for age and sex, 1.34 (95% CI 1.19-1.52). After adjustment for age, sex, and waist circumference, the standardized ORs for incident observed apnea were identical for fasting insulin and the homeostasis model assessment of insulin resistance: 1.31 (1.13-1.51) and 1.24 (1.09-1.41) for triglycerides and 1.52 (1.12-2.05) for smoking. Observed apnea at baseline was not associated with changes in anthropometric or biological parameters over the 6-year follow-up. CONCLUSIONS The most important baseline risk factor for incident apnea was adiposity. After accounting for adiposity, other risk factors were high insulin, insulin resistance, high triglycerides, and smoking, factors amenable to lifestyle intervention.
Collapse
Affiliation(s)
- Beverley Balkau
- Institut Nationale de la Santé et de la Recherché Médicale, CESP Centre for Research in Epidemiology and Population Health, Unité 1018, Epidemiology of diabetes, obesity and chronic kidney disease over the lifecourse, Villejuif, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Fontaine‐Bisson B, Fumeron F, Marre M, Dutour A, Badens C, Levy N, Tichet J, Tregouet D, Balkau B, Morange P. Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR Prospective Study. FASEB J 2010. [DOI: 10.1096/fasebj.24.1_supplement.822.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - Michel Marre
- Xavier Bichat Medical School, INSERM U695ParisFrance
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Mägi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JRB, Egan JM, Lajunen T, Grarup N, Sparsø T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proença C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O’Connell J, Luan J, Elliott A, McCarroll SA, Payne F, Roccasecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, Beilby JP, Ben-Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Böttcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen YDI, Chines P, Clarke R, Coin LJM, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day INM, de Geus E, Delplanque J, Dina C, Erdos MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Groves CJ, Grundy S, Gwilliam R, Gyllensten U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen AL, Hassanali N, Hayward C, Heath SC, Hercberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa B, Johnson PRV, Jørgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, Lecoeur C, Li Y, Lyssenko V, Mahley R, Mangino M, Manning AK, Martínez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orrù M, Pakyz R, Palmer CNA, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AFH, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott LJ, Seedorf U, Sharp SJ, Shields B, Sigurðsson G, Sijbrands EJG, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, Syvänen AC, Tanaka T, Thorand B, Tichet J, Tönjes A, Tuomi T, Uitterlinden AG, van Dijk KW, van Hoek M, Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H, Weedon MN, Wild SH, Willemsen G, Witteman JCM, Yarnell JWG, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC, Borecki IB, Loos RJF, Meneton P, Magnusson PKE, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Ríos M, Morris AD, Lind L, Palmer LJ, Hu FB, Franks PW, Ebrahim S, Marmot M, Kao WHL, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T, Pedersen O, Pramstaller PP, Wichmann HE, Illig T, Rudan I, Wright AF, Stumvoll M, Campbell H, Wilson JF, Hamsten A, Bergman RN, Buchanan TA, Collins FS, Mohlke KL, Tuomilehto J, Valle TT, Altshuler D, Rotter JI, Siscovick DS, Penninx BWJH, Boomsma D, Deloukas P, Spector TD, Frayling TM, Ferrucci L, Kong A, Thorsteinsdottir U, Stefansson K, van Duijn CM, Aulchenko YS, Cao A, Scuteri A, Schlessinger D, Uda M, Ruokonen A, Jarvelin MR, Waterworth DM, Vollenweider P, Peltonen L, Mooser V, Abecasis GR, Wareham NJ, Sladek R, Froguel P, Watanabe RM, Meigs JB, Groop L, Boehnke M, McCarthy MI, Florez JC, Barroso I. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42:105-16. [PMID: 20081858 PMCID: PMC3018764 DOI: 10.1038/ng.520] [Citation(s) in RCA: 1655] [Impact Index Per Article: 118.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2009] [Accepted: 10/14/2009] [Indexed: 02/08/2023]
Abstract
Levels of circulating glucose are tightly regulated. To identify new loci influencing glycemic traits, we performed meta-analyses of 21 genome-wide association studies informative for fasting glucose, fasting insulin and indices of beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) in up to 46,186 nondiabetic participants. Follow-up of 25 loci in up to 76,558 additional subjects identified 16 loci associated with fasting glucose and HOMA-B and two loci associated with fasting insulin and HOMA-IR. These include nine loci newly associated with fasting glucose (in or near ADCY5, MADD, ADRA2A, CRY2, FADS1, GLIS3, SLC2A2, PROX1 and C2CD4B) and one influencing fasting insulin and HOMA-IR (near IGF1). We also demonstrated association of ADCY5, PROX1, GCK, GCKR and DGKB-TMEM195 with type 2 diabetes. Within these loci, likely biological candidate genes influence signal transduction, cell proliferation, development, glucose-sensing and circadian regulation. Our results demonstrate that genetic studies of glycemic traits can identify type 2 diabetes risk loci, as well as loci containing gene variants that are associated with a modest elevation in glucose levels but are not associated with overt diabetes.
Collapse
Affiliation(s)
- Josée Dupuis
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118, USA
- National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, Massachusetts 01702, USA
| | - Claudia Langenberg
- MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
| | - Inga Prokopenko
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
| | - Richa Saxena
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
| | - Nicole Soranzo
- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
- Twin Research & Genetic Epidemiology Department, King’s College London, St Thomas' Hospital Campus, Lambeth Palace Rd, London SE1 7EH, UK
| | - Anne U Jackson
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA
| | - Eleanor Wheeler
- Metabolic Disease Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | - Nicole L Glazer
- Cardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, Washington, USA
| | - Nabila Bouatia-Naji
- CNRS-UMR8090, Pasteur Institute, Lille 2-Droit et Santé University, F-59000 Lille, France
| | - Anna L Gloyn
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
| | - Cecilia M Lindgren
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
| | - Reedik Mägi
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
| | - Andrew P Morris
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
| | - Joshua Randall
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
| | - Toby Johnson
- Department of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland
- University Institute of Social and Preventative Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, 1005 Lausanne, Switzerland
- Swiss Institute of Bioinformatics, Switzerland
| | - Paul Elliott
- Department of Epidemiology and Public Health, Imperial College of London, Faculty of Medicine, Norfolk Place, London W2 1PG, UK
| | - Denis Rybin
- Boston University Data Coordinating Center, Boston, Massachusetts 02118, USA
| | | | | | - Peter Henneman
- Department of Human Genetics, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands
| | - Harald Grallert
- Institute of Epidemiology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - Abbas Dehghan
- Department of Epidemiology, Erasmus MC Rotterdam, 3000 CA, The Netherlands
| | - Jouke Jan Hottenga
- Department of Biological Psychology, VU, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands
| | | | - Pau Navarro
- MRC Human Genetics Unit, IGMM, Edinburgh EH4 2XU, UK
| | - Kijoung Song
- Division of Genetics, R&D, Glaxo SmithKline, King of Prussia, Pennsylvania 19406, USA
| | - Anuj Goel
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
- Department of Cardiovascular Medicine, University of Oxford, Oxford OX3 9DU, UK
| | - John R B Perry
- Genetics of Complex Traits, Institute of Biomedical and Clinical Sciences, Peninsula College of Medicine and Dentistry, University of Exeter EX1 2LU, UK
| | - Josephine M Egan
- Laboratory of Clinical Investigation, National Institute of Aging, Baltimore, Maryland 21250, USA
| | - Taina Lajunen
- Unit for Child and Adolescent Health and Welfare, National Institute for Health and Welfare, Biocenter Oulu, University of Oulu, 90014 Oulu, Finland
| | - Niels Grarup
- Hagedorn Research Institute, 2820 Gentofte, Denmark
| | | | - Alex Doney
- Department of Medicine & Therapeutics, Level 7, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK
| | - Benjamin F Voight
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
| | - Heather M Stringham
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA
| | - Man Li
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21287, USA
| | - Stavroula Kanoni
- Department of Nutrition - Dietetics, Harokopio University, 17671 Athens, Greece
| | - Peter Shrader
- General Medicine Division, Massachusetts General Hospital, Boston, Massachusetts, USA
| | | | - Meena Kumari
- Department of Epidemiology and Public Health, University College London, UK
| | - Lu Qi
- Depts. of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
| | - Nicholas J Timpson
- MRC Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol BS8 2PR, UK
| | - Christian Gieger
- Institute of Epidemiology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - Carina Zabena
- Fundación para la Investigación Biomédica del Hospital Clínico San Carlos, Madrid, Spain
| | - Ghislain Rocheleau
- Departments of Medicine and Human Genetics, McGill University, Montreal, Canada
- Genome Quebec Innovation Centre, Montreal H3A 1A4, Canada
| | - Erik Ingelsson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
| | - Ping An
- Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Jeffrey O’Connell
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
| | - Jian'an Luan
- MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
| | - Amanda Elliott
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
| | - Steven A McCarroll
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
| | - Felicity Payne
- Metabolic Disease Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | - Rosa Maria Roccasecca
- Metabolic Disease Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | - François Pattou
- INSERM U859, Universite de Lille-Nord de France, F-59000 Lille, France
| | - Praveen Sethupathy
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - Kristin Ardlie
- The Broad Institute, Cambridge, Massachusetts 02141, USA
| | - Yavuz Ariyurek
- Leiden Genome Technology Center, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
| | - Beverley Balkau
- INSERM U780-IFR69, Paris Sud University, F-94807 Villejuif, France
| | - Philip Barter
- The Heart Research Institute, Sydney, New South Wales, Australia
| | - John P Beilby
- PathWest Laboratory of Western Australia, Department of Molecular Genetics, J Block, QEII Medical Centre, NEDLANDS WA 6009, Australia
- School of Surgery and Pathology, University of Western Australia, Nedlands WA 6009, Australia
| | - Yoav Ben-Shlomo
- Department of Social Medicine, University of Bristol, Bristol BS8 2PR, UK
| | - Rafn Benediktsson
- Landspitali University Hospital, 101 Reykjavik, Iceland
- Icelandic Heart Association, 201 Kopavogur, Iceland
| | - Amanda J Bennett
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
| | - Sven Bergmann
- Department of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland
- University Institute of Social and Preventative Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, 1005 Lausanne, Switzerland
| | - Murielle Bochud
- University Institute of Social and Preventative Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, 1005 Lausanne, Switzerland
| | - Eric Boerwinkle
- The Human Genetics Center and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas 77030, USA
| | - Amélie Bonnefond
- CNRS-UMR8090, Pasteur Institute, Lille 2-Droit et Santé University, F-59000 Lille, France
| | - Lori L Bonnycastle
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - Knut Borch-Johnsen
- Steno Diabetes Center, DK-2820 Gentofte, Copenhagen, Denmark
- Faculty of Health Science, University of Aarhus, Aarhus DK-8000, Denmark
| | - Yvonne Böttcher
- Department of Medicine, University of Leipzig, Liebigstr. 18, 04103 Leipzig, Germany
| | - Eric Brunner
- Department of Epidemiology and Public Health, University College London, UK
| | | | | | - Yii-Der Ida Chen
- Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Peter Chines
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - Robert Clarke
- Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF, UK
| | - Lachlan J M Coin
- Department of Epidemiology and Public Health, Imperial College of London, Faculty of Medicine, Norfolk Place, London W2 1PG, UK
| | - Matthew N Cooper
- Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Perth, Australia
| | - Marilyn Cornelis
- Depts. of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
| | - Gabe Crawford
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA
| | - Laura Crisponi
- Istituto di Neurogenetica e Neurofarmacologia (INN), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari 09042, Italy
| | - Ian N M Day
- MRC Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol BS8 2PR, UK
| | - Eco de Geus
- Department of Biological Psychology, VU, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands
| | - Jerome Delplanque
- CNRS-UMR8090, Pasteur Institute, Lille 2-Droit et Santé University, F-59000 Lille, France
| | - Christian Dina
- CNRS-UMR8090, Pasteur Institute, Lille 2-Droit et Santé University, F-59000 Lille, France
| | - Michael R Erdos
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - Annette C Fedson
- Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Perth, Australia
- Western Australian Sleep Disorders Research Institute, Queen Elizabeth Medical Centre II, Perth, Australia
| | - Antje Fischer-Rosinsky
- Department of Endocrinology, Diabetes and Nutrition, Charite-Universitaetsmedizin Berlin, Berlin, Germany
- Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
| | - Nita G Forouhi
- MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
| | - Caroline S Fox
- National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, Massachusetts 01702, USA
- Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Rune Frants
- Department of Human Genetics, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands
| | - Maria Grazia Franzosi
- Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy
| | - Pilar Galan
- U557 Institut National de la Santé et de la Recherche Médicale, U1125 Institut National de la Recherche Agronomique, Université Paris 13, 74 rue Marcel Cachin, 93017 Bobigny Cedex, France
| | - Mark O Goodarzi
- Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Jürgen Graessler
- Department of Medicine III, Division Prevention and Care of Diabetes, University of Dresden, 01307 Dresden
| | - Christopher J Groves
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
| | - Scott Grundy
- Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Rhian Gwilliam
- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | - Ulf Gyllensten
- Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, S-751 85 Uppsala, Sweden
| | - Samy Hadjadj
- CHU de Poitiers, Endocrinologie Diabetologie, CIC INSERM 0802, INSERM U927, Université de Poitiers, UFR, Médecine Pharmacie, Poitiers, France
| | - Göran Hallmans
- Department of Public Health & Clinical Medicine, Section for Nutritional Research, Umeå University, Umeå, Sweden
| | - Naomi Hammond
- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | - Xijing Han
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA
| | - Anna-Liisa Hartikainen
- Department of Clinical Sciences, Obstetrics and Gynecology, University of Oulu, Box 5000, Fin-90014 University of Oulu, Finland
| | - Neelam Hassanali
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
| | | | - Simon C Heath
- Centre National de Génotypage/IG/CEA, 2 rue Gaston Crémieux CP 5721, 91057 Evry Cedex, France
| | - Serge Hercberg
- U872 Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine Paris Descartes, 15 rue de l’Ecole de Médecine, 75270 Paris Cedex, France
| | - Christian Herder
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
| | - Andrew A Hicks
- Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Viale Druso 1, 39100 Bolzano, Italy, Affiliated Institute of the University Lübeck, Germany
| | - David R Hillman
- Western Australian Sleep Disorders Research Institute, Queen Elizabeth Medical Centre II, Perth, Australia
- Department of Pulmonary Physiology, Sir Charles Gairdner Hospital, Perth, Australia
| | - Aroon D Hingorani
- Department of Epidemiology and Public Health, University College London, UK
| | - Albert Hofman
- Department of Epidemiology, Erasmus MC Rotterdam, 3000 CA, The Netherlands
| | - Jennie Hui
- PathWest Laboratory of Western Australia, Department of Molecular Genetics, J Block, QEII Medical Centre, NEDLANDS WA 6009, Australia
- Busselton Population Medical Research Foundation, Sir Charles Gairdner Hospital, Perth, Australia
| | - Joe Hung
- Heart Institute of Western Australia, Sir Charles Gairdner Hospital, Nedlands WA 6009, Australia
- School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009, Australia
| | - Bo Isomaa
- Folkhalsan Research Centre, Helsinki, Finland
- Malmska Municipal Health Care Center and Hospital, Jakobstad, Finland
| | - Paul R V Johnson
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
- Nuffield Department of Surgery, University of Oxford, Oxford OX3 9DU, UK
| | - Torben Jørgensen
- Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark
- Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
| | - Antti Jula
- National Institute for Health and Welfare, Unit of Population Studies, Turku, Finland
| | - Marika Kaakinen
- Institute of Health Sciences and Biocenter Oulu, Box 5000, Fin-90014 University of Oulu, Finland
| | - Jaakko Kaprio
- Department of Public Health, Faculty of Medicine, P.O. Box 41 (Mannerheimintie 172), University of Helsinki, 00014 Helsinki, Finland
- National Institute for Health and Welfare, Unit for Child and Adolescent Mental Health, Helsinki, Finland
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
| | | | - Mika Kivimaki
- Department of Epidemiology and Public Health, University College London, UK
| | - Beatrice Knight
- Diabetes Genetics, Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter EX2 5DW, UK
| | - Seppo Koskinen
- National Institute for Health and Welfare, Unit of Living Conditions, Health and Wellbeing, Helsinki, Finland
| | - Peter Kovacs
- Interdisciplinary Centre for Clinical Research, University of Leipzig, Inselstr. 22, 04103 Leipzig, Germany
| | - Kirsten Ohm Kyvik
- The Danish Twin Registry, Epidemiology, Institute of Public Health, University of Southern Denmark, J.B. Winsløws Vej 9B, 5000 Odense, Denmark
| | - G Mark Lathrop
- Centre National de Génotypage/IG/CEA, 2 rue Gaston Crémieux CP 5721, 91057 Evry Cedex, France
| | - Debbie A Lawlor
- MRC Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol BS8 2PR, UK
| | - Olivier Le Bacquer
- CNRS-UMR8090, Pasteur Institute, Lille 2-Droit et Santé University, F-59000 Lille, France
| | - Cécile Lecoeur
- CNRS-UMR8090, Pasteur Institute, Lille 2-Droit et Santé University, F-59000 Lille, France
| | - Yun Li
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA
| | - Valeriya Lyssenko
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, University Hospital Malmo, Malmo, Sweden
| | - Robert Mahley
- Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, California, USA
| | - Massimo Mangino
- Twin Research & Genetic Epidemiology Department, King’s College London, St Thomas' Hospital Campus, Lambeth Palace Rd, London SE1 7EH, UK
| | - Alisa K Manning
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118, USA
| | | | - Jarred B McAteer
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA
- Diabetes Research Center (Diabetes Unit), Massachusetts General Hospital, Boston, Massachusetts 02114, USA
- Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Laura J McCulloch
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
| | - Ruth McPherson
- Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Christa Meisinger
- Institute of Epidemiology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - David Melzer
- Genetics of Complex Traits, Institute of Biomedical and Clinical Sciences, Peninsula College of Medicine and Dentistry, University of Exeter EX1 2LU, UK
| | - David Meyre
- CNRS-UMR8090, Pasteur Institute, Lille 2-Droit et Santé University, F-59000 Lille, France
| | - Braxton D Mitchell
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
| | - Mario A Morken
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - Sutapa Mukherjee
- Western Australian Sleep Disorders Research Institute, Queen Elizabeth Medical Centre II, Perth, Australia
- Department of Pulmonary Physiology, Sir Charles Gairdner Hospital, Perth, Australia
| | - Silvia Naitza
- Istituto di Neurogenetica e Neurofarmacologia (INN), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari 09042, Italy
| | - Narisu Narisu
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - Matthew J Neville
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LJ, UK
| | - Ben A Oostra
- Department of Clinical Genetics, Erasmus MC Rotterdam, 3000 CA, The Netherlands
| | - Marco Orrù
- Istituto di Neurogenetica e Neurofarmacologia (INN), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari 09042, Italy
| | - Ruth Pakyz
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
| | - Colin N A Palmer
- Biomedical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK
| | - Giuseppe Paolisso
- Department of Geriatric Medicine and Metabolic Disease, Second University of Naples, Naples, Italy
| | - Cristian Pattaro
- Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Viale Druso 1, 39100 Bolzano, Italy, Affiliated Institute of the University Lübeck, Germany
| | - Daniel Pearson
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - John F Peden
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
- Department of Cardiovascular Medicine, University of Oxford, Oxford OX3 9DU, UK
| | - Nancy L. Pedersen
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Markus Perola
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
- National Institute for Health and Welfare, Unit of Public Health Genomics, Helsinki, Finland
- Department of Medical Genetics, University of Helsinki, Helsinki, Finland
| | - Andreas F H Pfeiffer
- Department of Endocrinology, Diabetes and Nutrition, Charite-Universitaetsmedizin Berlin, Berlin, Germany
- Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
| | - Irene Pichler
- Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Viale Druso 1, 39100 Bolzano, Italy, Affiliated Institute of the University Lübeck, Germany
| | - Ozren Polasek
- Department of Medical Statistics, Epidemiology and Medical Informatics, Andrija Stampar School of Public Health, Medical School, University of Zagreb, Rockefellerova 4, 10000 Zagreb, Croatia
| | - Danielle Posthuma
- Department of Biological Psychology, VU, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands
- Department of Clinical Genetics, VUMC, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
| | - Simon C Potter
- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | - Anneli Pouta
- Department of Obstetrics and Gynaecology, Oulu University Hospital, Oulu, Finland
| | - Michael A Province
- Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Bruce M Psaty
- Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, Washington, USA
- Group Health Center for Health Studies, Seattle, Washington, USA
| | - Wolfgang Rathmann
- Institute of Biometrics and Epidemiology, German Diabetes Centre, Leibniz Centre at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - Nigel W Rayner
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
| | - Kenneth Rice
- Department of Biostatistics, University of Washington, Seattle, Washington 98195, USA
| | - Samuli Ripatti
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
- National Institute for Health and Welfare, Unit of Public Health Genomics, Helsinki, Finland
| | - Fernando Rivadeneira
- Department of Epidemiology, Erasmus MC Rotterdam, 3000 CA, The Netherlands
- Department of Internal Medicine, Erasmus MC Rotterdam, 3000 CA, The Netherlands
| | - Michael Roden
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
- Department of Medicine/Metabolic Diseases, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
| | - Olov Rolandsson
- Department of Public Health & Clinical Medicine, Section for Family Medicine, Umeå University Hospital, Umeå, Sweden
| | - Annelli Sandbaek
- School of Public Health, Department of General Practice, University of Aarhus, Aarhus DK-8000, Denmark
| | - Manjinder Sandhu
- MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
- Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK
| | - Serena Sanna
- Istituto di Neurogenetica e Neurofarmacologia (INN), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari 09042, Italy
| | - Avan Aihie Sayer
- MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - Paul Scheet
- Department of Epidemiology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, USA
| | - Laura J Scott
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA
| | - Udo Seedorf
- Leibniz-Institut für Arterioskleroseforschung an der Universität Münster,Münster, Germany
| | - Stephen J Sharp
- MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
| | - Beverley Shields
- Diabetes Genetics, Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter EX2 5DW, UK
| | - Gunnar Sigurðsson
- Landspitali University Hospital, 101 Reykjavik, Iceland
- Icelandic Heart Association, 201 Kopavogur, Iceland
| | - Erik J G Sijbrands
- Department of Epidemiology, Erasmus MC Rotterdam, 3000 CA, The Netherlands
- Department of Internal Medicine, Erasmus MC Rotterdam, 3000 CA, The Netherlands
| | - Angela Silveira
- Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Laila Simpson
- Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Perth, Australia
- Western Australian Sleep Disorders Research Institute, Queen Elizabeth Medical Centre II, Perth, Australia
| | - Andrew Singleton
- Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland 20892, USA
| | - Nicholas L Smith
- Department of Epidemiology, University of Washington, Seattle, Washington 98195, USA
- Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle, Washington, USA
| | - Ulla Sovio
- Department of Epidemiology and Public Health, Imperial College of London, Faculty of Medicine, Norfolk Place, London W2 1PG, UK
| | - Amy Swift
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - Holly Syddall
- MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | | | - Toshiko Tanaka
- Medstar Research Institute, Baltimore, Maryland 21250, USA
- Clinical Research Branch, National Institute on Aging, Baltimore, Maryland 21250, USA
| | - Barbara Thorand
- Institute of Epidemiology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - Jean Tichet
- Institut interrégional pour la santé (IRSA), F-37521 La Riche, France
| | - Anke Tönjes
- Department of Medicine, University of Leipzig, Liebigstr. 18, 04103 Leipzig, Germany
- Coordination Centre for Clinical Trials, University of Leipzig, Härtelstr. 16-18, 04103 Leipzig, Germany
| | - Tiinamaija Tuomi
- Folkhalsan Research Centre, Helsinki, Finland
- Department of Medicine, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - André G Uitterlinden
- Department of Epidemiology, Erasmus MC Rotterdam, 3000 CA, The Netherlands
- Department of Internal Medicine, Erasmus MC Rotterdam, 3000 CA, The Netherlands
| | - Ko Willems van Dijk
- Department of Human Genetics, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands
- Department of Internal Medicine, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands
| | - Mandy van Hoek
- Department of Internal Medicine, Erasmus MC Rotterdam, 3000 CA, The Netherlands
| | - Dhiraj Varma
- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | - Sophie Visvikis-Siest
- Research Unit, Cardiovascular Genetics, Nancy University Henri Poincaré, Nancy, France
| | | | - Nicole Vogelzangs
- EMGO Institute/Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands
| | - Gérard Waeber
- Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
| | - Peter J Wagner
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
- National Institute for Health and Welfare, Unit of Public Health Genomics, Helsinki, Finland
| | - Andrew Walley
- Genomic Medicine, Imperial College London, Hammersmith Hospital, W12 0NN, London, UK
| | | | - Kim L Ward
- Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Perth, Australia
- Western Australian Sleep Disorders Research Institute, Queen Elizabeth Medical Centre II, Perth, Australia
| | - Hugh Watkins
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
- Department of Cardiovascular Medicine, University of Oxford, Oxford OX3 9DU, UK
| | - Michael N Weedon
- Genetics of Complex Traits, Institute of Biomedical and Clinical Sciences, Peninsula College of Medicine and Dentistry, University of Exeter EX1 2LU, UK
| | - Sarah H Wild
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK
| | - Gonneke Willemsen
- Department of Biological Psychology, VU, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands
| | | | - John W G Yarnell
- Epidemiology & Public Health, Queen's University Belfast, Belfast BT12 6BJ, UK
| | - Eleftheria Zeggini
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | - Diana Zelenika
- Centre National de Génotypage/IG/CEA, 2 rue Gaston Crémieux CP 5721, 91057 Evry Cedex, France
| | - Björn Zethelius
- Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
- Medical Products Agency, Uppsala, Sweden
| | - Guangju Zhai
- Twin Research & Genetic Epidemiology Department, King’s College London, St Thomas' Hospital Campus, Lambeth Palace Rd, London SE1 7EH, UK
| | - Jing Hua Zhao
- MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
| | - M Carola Zillikens
- Department of Internal Medicine, Erasmus MC Rotterdam, 3000 CA, The Netherlands
| | | | | | | | - Ingrid B Borecki
- Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Ruth J F Loos
- MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
| | - Pierre Meneton
- U872 Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine Paris Descartes, 15 rue de l’Ecole de Médecine, 75270 Paris Cedex, France
| | - Patrik K E Magnusson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - David M Nathan
- Diabetes Research Center (Diabetes Unit), Massachusetts General Hospital, Boston, Massachusetts 02114, USA
- Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Gordon H Williams
- Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
- Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Andrew T Hattersley
- Diabetes Genetics, Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter EX2 5DW, UK
| | - Kaisa Silander
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
- National Institute for Health and Welfare, Unit of Public Health Genomics, Helsinki, Finland
| | - Veikko Salomaa
- National Institute for Health and Welfare, Unit of Chronic Disease Epidemiology and Prevention, Helsinki, Finland
| | - George Davey Smith
- MRC Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol BS8 2PR, UK
| | - Stefan R Bornstein
- Department of Medicine III, Division Prevention and Care of Diabetes, University of Dresden, 01307 Dresden
| | - Peter Schwarz
- Department of Medicine III, Division Prevention and Care of Diabetes, University of Dresden, 01307 Dresden
| | - Joachim Spranger
- Department of Endocrinology, Diabetes and Nutrition, Charite-Universitaetsmedizin Berlin, Berlin, Germany
- Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
| | - Fredrik Karpe
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LJ, UK
| | - Alan R Shuldiner
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
| | - Cyrus Cooper
- MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
| | - George V Dedoussis
- Department of Nutrition - Dietetics, Harokopio University, 17671 Athens, Greece
| | - Manuel Serrano-Ríos
- Fundación para la Investigación Biomédica del Hospital Clínico San Carlos, Madrid, Spain
| | - Andrew D Morris
- Biomedical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK
| | - Lars Lind
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden
| | - Lyle J Palmer
- Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Perth, Australia
- Western Australian Sleep Disorders Research Institute, Queen Elizabeth Medical Centre II, Perth, Australia
- Busselton Population Medical Research Foundation, Sir Charles Gairdner Hospital, Perth, Australia
| | - Frank B. Hu
- Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
- Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Paul W Franks
- Genetic Epidemiology & Clinical Research Group, Department of Public Health & Clinical Medicine, Section for Medicine, Umeå University Hospital, Umeå, Sweden
| | - Shah Ebrahim
- London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
| | - Michael Marmot
- Department of Epidemiology and Public Health, University College London, UK
| | - W H Linda Kao
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21287, USA
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21287, USA
- The Welch Center for Prevention, Epidemiology, and Clinical Research, School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21287, USA
| | - James S Pankow
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota 55454, USA
| | - Michael J Sampson
- Department of Endocrinology and Diabetes, Norfolk and Norwich University Hospital NHS Trust, Norwich, NR1 7UY, UK
| | - Johanna Kuusisto
- Department of Medicine, University of Kuopio and Kuopio University Hospital, Kuopio 70210, Finland
| | - Markku Laakso
- Department of Medicine, University of Kuopio and Kuopio University Hospital, Kuopio 70210, Finland
| | - Torben Hansen
- Hagedorn Research Institute, 2820 Gentofte, Denmark
- Faculty of Health Science, University of Southern Denmark, Odense, Denmark
| | - Oluf Pedersen
- Hagedorn Research Institute, 2820 Gentofte, Denmark
- Faculty of Health Science, University of Aarhus, Aarhus DK-8000, Denmark
- Institute of Biomedical Science, Faculty of Health Science, University of Copenhagen, Denmark
| | - Peter Paul Pramstaller
- Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Viale Druso 1, 39100 Bolzano, Italy, Affiliated Institute of the University Lübeck, Germany
- Department of Neurology, General Central Hospital, 39100 Bolzano, Italy
- Department of Neurology, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
| | - H Erich Wichmann
- Institute of Epidemiology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany
- Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany
- Klinikum Grosshadern, Munich, Germany
| | - Thomas Illig
- Institute of Epidemiology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany
| | - Igor Rudan
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK
- School of Medicine, University of Split, Soltanska 2, 21000 Split, Croatia
- Gen-Info Ltd, Ruzmarinka 17, 10000 Zagreb, Croatia
| | - Alan F Wright
- MRC Human Genetics Unit, IGMM, Edinburgh EH4 2XU, UK
| | - Michael Stumvoll
- Department of Medicine, University of Leipzig, Liebigstr. 18, 04103 Leipzig, Germany
| | - Harry Campbell
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK
| | - James F Wilson
- Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK
| | - Anders Hamsten
- Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Richard N Bergman
- Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
| | - Thomas A Buchanan
- Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
- Department of Medicine, Division of Endocrinology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
| | - Francis S Collins
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - Karen L Mohlke
- Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - Jaakko Tuomilehto
- Department of Public Health, Faculty of Medicine, P.O. Box 41 (Mannerheimintie 172), University of Helsinki, 00014 Helsinki, Finland
- National Institute for Health and Welfare, Unit of Diabetes Prevention, Helsinki, Finland
| | - Timo T Valle
- National Institute for Health and Welfare, Unit of Diabetes Prevention, Helsinki, Finland
| | - David Altshuler
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
- Diabetes Research Center (Diabetes Unit), Massachusetts General Hospital, Boston, Massachusetts 02114, USA
- Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Jerome I Rotter
- Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - David S Siscovick
- Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, USA
| | - Brenda W J H Penninx
- EMGO Institute/Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands
| | - Dorret Boomsma
- Department of Biological Psychology, VU, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands
| | - Panos Deloukas
- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | - Timothy D Spector
- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
- Twin Research & Genetic Epidemiology Department, King’s College London, St Thomas' Hospital Campus, Lambeth Palace Rd, London SE1 7EH, UK
| | - Timothy M Frayling
- Genetics of Complex Traits, Institute of Biomedical and Clinical Sciences, Peninsula College of Medicine and Dentistry, University of Exeter EX1 2LU, UK
| | - Luigi Ferrucci
- Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, NIH, Baltimore, Maryland, USA
| | | | - Unnur Thorsteinsdottir
- deCODE Genetics, 101 Reykjavik, Iceland
- Faculty of Medicine, University of Iceland, 101 Reykjavík, Iceland
| | - Kari Stefansson
- deCODE Genetics, 101 Reykjavik, Iceland
- Faculty of Medicine, University of Iceland, 101 Reykjavík, Iceland
| | | | - Yurii S Aulchenko
- Department of Epidemiology, Erasmus MC Rotterdam, 3000 CA, The Netherlands
| | - Antonio Cao
- Istituto di Neurogenetica e Neurofarmacologia (INN), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari 09042, Italy
| | - Angelo Scuteri
- Istituto di Neurogenetica e Neurofarmacologia (INN), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari 09042, Italy
- Lab of Cardiovascular Sciences, National Institute on Aging, NIH, Baltimore, Maryland, USA
| | - David Schlessinger
- Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA
| | - Manuela Uda
- Istituto di Neurogenetica e Neurofarmacologia (INN), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Cagliari 09042, Italy
| | - Aimo Ruokonen
- Department of Clinical Sciences/Clinical Chemistry, University of Oulu, Box 5000, Fin-90014 University of Oulu, Finland
| | - Marjo-Riitta Jarvelin
- Department of Epidemiology and Public Health, Imperial College of London, Faculty of Medicine, Norfolk Place, London W2 1PG, UK
- Institute of Health Sciences and Biocenter Oulu, Box 5000, Fin-90014 University of Oulu, Finland
- National Institute of Health and Welfare, Aapistie 1, P.O. Box 310, Fin-90101 Oulu, Finland
| | - Dawn M Waterworth
- Division of Genetics, R&D, Glaxo SmithKline, King of Prussia, Pennsylvania 19406, USA
| | - Peter Vollenweider
- Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
| | - Leena Peltonen
- Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
- The Broad Institute, Cambridge, Massachusetts 02141, USA
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
- National Institute for Health and Welfare, Unit of Public Health Genomics, Helsinki, Finland
- Department of Medical Genetics, University of Helsinki, Helsinki, Finland
| | - Vincent Mooser
- Division of Genetics, R&D, Glaxo SmithKline, King of Prussia, Pennsylvania 19406, USA
| | - Goncalo R Abecasis
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA
| | - Nicholas J Wareham
- MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
| | - Robert Sladek
- Departments of Medicine and Human Genetics, McGill University, Montreal, Canada
- Genome Quebec Innovation Centre, Montreal H3A 1A4, Canada
| | - Philippe Froguel
- CNRS-UMR8090, Pasteur Institute, Lille 2-Droit et Santé University, F-59000 Lille, France
- Genomic Medicine, Imperial College London, Hammersmith Hospital, W12 0NN, London, UK
| | - Richard M Watanabe
- Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, 90033, USA
| | - James B Meigs
- General Medicine Division, Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Leif Groop
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, University Hospital Malmo, Malmo, Sweden
| | - Michael Boehnke
- Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan 48109, USA
| | - Mark I McCarthy
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LJ, UK
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LJ, UK
| | - Jose C Florez
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts 02142, USA
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
- Diabetes Research Center (Diabetes Unit), Massachusetts General Hospital, Boston, Massachusetts 02114, USA
- Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Inês Barroso
- Metabolic Disease Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
| | | |
Collapse
|
38
|
Gautier A, Balkau B, Lange C, Tichet J, Bonnet F. Risk factors for incident type 2 diabetes in individuals with a BMI of <27 kg/m2: the role of gamma-glutamyltransferase. Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetologia 2010; 53:247-53. [PMID: 19936701 DOI: 10.1007/s00125-009-1602-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2009] [Accepted: 10/08/2009] [Indexed: 01/30/2023]
Abstract
AIMS/HYPOTHESIS Risk factors for incident type 2 diabetes, in particular, hepatic markers, have rarely been studied in leaner individuals. We aimed to identify the metabolic and hepatic markers associated with incident diabetes in men and women with a BMI of <27 kg/m(2) and to compare them with those in individuals with a BMI of >or=27 kg/m(2). METHODS Risk factors for 9 year incident diabetes were compared in the French Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Comparisons were made between the 2,947 participants with a BMI of <27 kg/m(2) and the 879 with a BMI of >or=27 kg/m(2). RESULTS There were 92 incident cases of diabetes in individuals with a BMI of <27 kg/m(2) and 111 in those with a BMI of >or=27 kg/m(2). Among those who were not markedly overweight, classical biological markers were associated with 9 year incident diabetes, glycaemia being the strongest predictor. gamma-Glutamyltransferase (GGT), either considered as a continuous variable or at levels >or=20 U/l, was associated with incident diabetes, with a stronger effect in the BMI <27 kg/m(2) group: OR 1.59 (95% CI 1.29-1.97, p < 0.001) in comparison with OR 1.07 (95% CI 0.82-1.38, p = 0.63) for those with a BMI of >or=27 kg/m(2) (results after adjustment for alcohol intake, alanine aminotransferase, waist circumference and the HOMA insulin resistance index). CONCLUSIONS/INTERPRETATION In individuals with a BMI of <27 kg/m(2), GGT was the strongest predictor of diabetes after fasting hyperglycaemia. This association with incident diabetes remained after adjustment for conventional markers of insulin resistance, suggesting potential interactions between GGT, enhanced hepatic neoglucogenesis and/or early alterations of insulin secretion.
Collapse
Affiliation(s)
- A Gautier
- Service Endocrinologie, CHU Rennes, Hôpital Sud, 16 Boulevard de Bulgarie, 35203 Rennes, France
| | | | | | | | | | | |
Collapse
|
39
|
Bonnefond A, Vaxillaire M, Labrune Y, Lecoeur C, Chèvre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, Riveline JP, Hadjadj S, Gallois Y, Czernichow S, Hercberg S, Kaakinen M, Wiesner S, Charpentier G, Lévy-Marchal C, Elliott P, Jarvelin MR, Horber F, Dina C, Pedersen O, Sladek R, Meyre D, Froguel P. Genetic variant in HK1 is associated with a proanemic state and A1C but not other glycemic control-related traits. Diabetes 2009; 58:2687-97. [PMID: 19651813 PMCID: PMC2768183 DOI: 10.2337/db09-0652] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
OBJECTIVE A1C is widely considered the gold standard for monitoring effective blood glucose levels. Recently, a genome-wide association study reported an association between A1C and rs7072268 within HK1 (encoding hexokinase 1), which catalyzes the first step of glycolysis. HK1 deficiency in erythrocytes (red blood cells [RBCs]) causes severe nonspherocytic hemolytic anemia in both humans and mice. RESEARCH DESIGN AND METHODS The contribution of rs7072268 to A1C and the RBC-related traits was assessed in 6,953 nondiabetic European participants. We additionally analyzed the association with hematologic traits in 5,229 nondiabetic European individuals (in whom A1C was not measured) and 1,924 diabetic patients. Glucose control-related markers other than A1C were analyzed in 18,694 nondiabetic European individuals. A type 2 diabetes case-control study included 7,447 French diabetic patients. RESULTS Our study confirms a strong association between the rs7072268-T allele and increased A1C (beta = 0.029%; P = 2.22 x 10(-7)). Surprisingly, despite adequate study power, rs7072268 showed no association with any other markers of glucose control (fasting- and 2-h post-OGTT-related parameters, n = 18,694). In contrast, rs7072268-T allele decreases hemoglobin levels (n = 13,416; beta = -0.054 g/dl; P = 3.74 x 10(-6)) and hematocrit (n = 11,492; beta = -0.13%; P = 2.26 x 10(-4)), suggesting a proanemic effect. The T allele also increases risk for anemia (836 cases; odds ratio 1.13; P = 0.018). CONCLUSIONS HK1 variation, although strongly associated with A1C, does not seem to be involved in blood glucose control. Since HK1 rs7072268 is associated with reduced hemoglobin levels and favors anemia, we propose that HK1 may influence A1C levels through its anemic effect or its effect on glucose metabolism in RBCs. These findings may have implications for type 2 diabetes diagnosis and clinical management because anemia is a frequent complication of the diabetes state.
Collapse
Affiliation(s)
- Amélie Bonnefond
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
| | - Martine Vaxillaire
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
| | - Yann Labrune
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
| | - Cécile Lecoeur
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
| | - Jean-Claude Chèvre
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
| | - Nabila Bouatia-Naji
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
| | - Stéphane Cauchi
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
| | - Beverley Balkau
- INSERM U780, Villejuif, France, and University Paris-Sud, Orsay, France
| | - Michel Marre
- Department of Endocrinology, Diabetology and Nutrition, Bichat-Claude Bernard University Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France
- INSERM U695, Université Paris 7, Paris, France
| | - Jean Tichet
- Institut Inter-Régional Pour la Santé, La Riche, France
| | | | - Samy Hadjadj
- CHU de Poitiers, Endocrinologie Diabétologie, CIC INSERM 0802, INSERM U927, Université de Poitiers, UFR Médecine Pharmacie, Poitiers, France
| | - Yves Gallois
- CHU d'Angers, the Biochemistry Laboratory, Angers, France
| | - Sébastien Czernichow
- Unité de Recherche en Epidémiologie Nutritionnelle, INSERM U557, INRA U1125, CNAM, UP13, CRNH-IdF, and the Public Health Department, Hôpital Avicenne (AP-HP), Bobigny, France
| | - Serge Hercberg
- Unité de Recherche en Epidémiologie Nutritionnelle, INSERM U557, INRA U1125, CNAM, UP13, CRNH-IdF, and the Public Health Department, Hôpital Avicenne (AP-HP), Bobigny, France
| | - Marika Kaakinen
- Institute of Health Sciences, University of Oulu, Oulu, Finland
- Biocenter Oulu, University of Oulu, Oulu, Finland
| | - Susanne Wiesner
- Klinik Lindberg, Winterthur, Switzerland
- University Berne, Berne, Switzerland
| | | | - Claire Lévy-Marchal
- INSERM U690, Robert Debré Hospital, Paris, France
- Paris Diderot University, Paris, France
| | - Paul Elliott
- Department of Epidemiology and Public Health, Imperial College London, London, U.K
| | - Marjo-Riitta Jarvelin
- Unité de Recherche en Epidémiologie Nutritionnelle, INSERM U557, INRA U1125, CNAM, UP13, CRNH-IdF, and the Public Health Department, Hôpital Avicenne (AP-HP), Bobigny, France
- Department of Epidemiology and Public Health, Imperial College London, London, U.K
| | - Fritz Horber
- Klinik Lindberg, Winterthur, Switzerland
- University Berne, Berne, Switzerland
| | - Christian Dina
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
| | - Oluf Pedersen
- Steno Diabetes Center, Gentofte, Denmark
- Department of Health Sciences, University of Aarhus, Aarhus, Denmark
- Department of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Robert Sladek
- Department of Human Genetics, McGill University, Montreal, Canada
- Genome Quebec Innovation Centre, Montreal, Canada
| | - David Meyre
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
| | - Philippe Froguel
- CNRS-UMR-8090, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France
- Genomic Medicine, Hammersmith Hospital, Imperial College London, London, U.K
- Corresponding author: Philippe Froguel,
| |
Collapse
|
40
|
Cogneau J, Lebeau JP, Tichet J, Lange C, Balkau B. [Drug treatment of cardiovascular risk factors over six years of following the French DESIR cohort]. Sante Publique 2009; 21:547-559. [PMID: 20429225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
OBJECTIVE To describe the treatment of cardiovascular risk factors within the context of a cohort study of adults, according to the risk estimated by the Framingham equation. METHOD This prospective study, DESIR, followed 1526 men and 1652 women for six years. At the time of the study's initiation, all participants were aged 35 to 65, and none were being treated for hypertension or dyslipemia. Treatments for hypertension and dyslipemia initiated during the study were analyzed according to categories of cardiovascular risk based on the Framingham scale. RESULTS At baseline, 24% of men and 5% of women had an estimated 10 years cardiovascular risk (for CHD) higher or equal to 10%. Three years later, only 19% of these men and 36% of these women had been treated, while 6% of men and 9% of women at risk < 10% had also been treated well. At six years, one third of men at high risk at baseline and/or at three years were treated, against half of the women. CONCLUSION Despite a significant effort to communicate the importance of addressing and treating the individual risk factors, the currently prescribed treatments remain inadequate, especially given the necessity to treat them based on the assessment of the overall cardiovascular risk.
Collapse
Affiliation(s)
- Joël Cogneau
- Institut de Recherche en Médecine Générale, 7 passage Poncelet 75017 Paris, France
| | | | | | | | | |
Collapse
|
41
|
Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proença C, Bacot F, Balkau B, Belisle A, Borch-Johnsen K, Charpentier G, Dina C, Durand E, Elliott P, Hadjadj S, Järvelin MR, Laitinen J, Lauritzen T, Marre M, Mazur A, Meyre D, Montpetit A, Pisinger C, Posner B, Poulsen P, Pouta A, Prentki M, Ribel-Madsen R, Ruokonen A, Sandbaek A, Serre D, Tichet J, Vaxillaire M, Wojtaszewski JFP, Vaag A, Hansen T, Polychronakos C, Pedersen O, Froguel P, Sladek R. Erratum: Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 2009. [DOI: 10.1038/ng1009-1156c] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
42
|
Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proença C, Bacot F, Balkau B, Belisle A, Borch-Johnsen K, Charpentier G, Dina C, Durand E, Elliott P, Hadjadj S, Järvelin MR, Laitinen J, Lauritzen T, Marre M, Mazur A, Meyre D, Montpetit A, Pisinger C, Posner B, Poulsen P, Pouta A, Prentki M, Ribel-Madsen R, Ruokonen A, Sandbaek A, Serre D, Tichet J, Vaxillaire M, Wojtaszewski JFP, Vaag A, Hansen T, Polychronakos C, Pedersen O, Froguel P, Sladek R. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 2009; 41:1110-5. [PMID: 19734900 DOI: 10.1038/ng.443] [Citation(s) in RCA: 314] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2009] [Accepted: 07/13/2009] [Indexed: 12/22/2022]
Abstract
Genome-wide association studies have identified common variants that only partially explain the genetic risk for type 2 diabetes (T2D). Using genome-wide association data from 1,376 French individuals, we identified 16,360 SNPs nominally associated with T2D and studied these SNPs in an independent sample of 4,977 French individuals. We then selected the 28 best hits for replication in 7,698 Danish subjects and identified 4 SNPs showing strong association with T2D, one of which (rs2943641, P = 9.3 x 10(-12), OR = 1.19) was located adjacent to the insulin receptor substrate 1 gene (IRS1). Unlike previously reported T2D risk loci, which predominantly associate with impaired beta cell function, the C allele of rs2943641 was associated with insulin resistance and hyperinsulinemia in 14,358 French, Danish and Finnish participants from population-based cohorts; this allele was also associated with reduced basal levels of IRS1 protein and decreased insulin induction of IRS1-associated phosphatidylinositol-3-OH kinase activity in human skeletal muscle biopsies.
Collapse
Affiliation(s)
- Johan Rung
- McGill University and Génome Québec Innovation Centre, Montréal, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, Launoy G. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer 2009; 125:1127-33. [PMID: 19431212 DOI: 10.1002/ijc.24407] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Immunochemical faecal occult blood tests (I-FOBT) detect more effectively advanced neoplasia than guaiac tests (G-FOBT). The study aim was to compare the performance of an I-FOBT whilst varying the positivity threshold and considering four analysis modalities: one sample was performed (MG(1)), two samples were performed and at least one sample was positive (MG(2+)), both samples were positive (MG(2++)) or the mean of the two samples' log-transformed haemoglobin contents exceeded the cutoff (MG(2m)). Screening for colorectal cancer using both G-FOBT and two samples' I-FOBT was performed by an average-risk population sample of 20,322 subjects. Among the 1,615 subjects with at least one positive test, 1,277 had a satisfactory colonoscopy result; 43 invasive cancers and 270 high-risk adenomas were detected. The I-FOBT was reinterpreted under each analysis modality (a random selection of one sample led to MG(1)). For all modalities, increasing the positivity threshold decreased sensitivity and increased specificity. The relative ROC curves (in reference to G-FOBT) demonstrated similar performance for MG(1) and MG(2+), and improved performance for MG(2m). MG(2++) sensitivity was limited within the range of positivity thresholds evaluated. For any specificity, MG(2m) provided the highest sensitivity. For any sensitivity, MG(2m) provided the highest specificity. For any positivity rate, MG(2m) provided both the highest sensitivity and specificity. This study suggests the replacement of MG(2+) by MG(1) or, for even better performance, by MG(2m) provided that two samples are performed with similar participation (which should be explored). The targeted positivity rate could then be achieved by choosing the positivity threshold.
Collapse
Affiliation(s)
- Lydia Guittet
- Cancers & Populations, ERI INSERM, UFR Médecine, CHU, Caen, France.
| | | | | | | | | | | | | |
Collapse
|
44
|
Blakemore AIF, Meyre D, Delplanque J, Vatin V, Lecoeur C, Marre M, Tichet J, Balkau B, Froguel P, Walley AJ. A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity. Obesity (Silver Spring) 2009; 17:1549-53. [PMID: 19300429 DOI: 10.1038/oby.2009.75] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Visfatin was recently reported as a novel adipokine encoded by the NAMPT (PBEF1) gene. This study was aimed at investigation of the possibility that single-nucleotide polymorphisms (SNPs) in the visfatin gene are associated with either obesity or type 2 diabetes (T2D). A set of eight "tag-SNPs" were selected and ABI SNPlex assays designed for genotyping purposes. A total of 1,709 severely obese subjects were typed (896 class III obese adults and 813 children) together with 2,367 T2D individuals and 2,850 controls. For quantitative trait analysis, an additional 2,362 subjects were typed for rs10487818 from a general population sample. One rare SNP, rs10487818, located in intron 4 of NAMPT was associated with severe obesity, with a minor allele frequency of 1.6% in controls, 0.4% in the class III obese adults and, remarkably, 0% in the severely obese children. A highly significant association was observed for the presence or absence of the rare allele, i.e., (A,A) vs. (A,T + T,T) genotypes, in children (P = 6 x 10(-9)) and in adults (P = 8 x 10(-5)). No other significant (P < 0.05) association was observed with obesity or T2D for this or any other SNP. No association with BMI or waist-to-hip ratio was observed in a general population sample (n = 5,212). This is one of the first rare SNPs shown to be protective against a common polygenic disease and provides further evidence that rare alleles of strong effect can contribute to complex diseases such as severe obesity.
Collapse
|
45
|
Bonnet F, Balkau B, Malécot JM, Picard P, Lange C, Fumeron F, Aubert R, Raverot V, Déchaud H, Tichet J, Lecomte P, Pugeat M. Sex hormone-binding globulin predicts the incidence of hyperglycemia in women: interactions with adiponectin levels. Eur J Endocrinol 2009; 161:81-5. [PMID: 19429700 DOI: 10.1530/eje-09-0202] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Previous evidence has suggested that a low sex hormone-binding globulin (SHBG) concentration is associated with insulin-resistance and a low adiponectin concentration. We investigated the association between SHBG and the risk of hyperglycemia in each sex and we determined potential interactions between SHBG and adiponectin levels in the development of dysglycemia. DESIGN We used a nested case-control design in the large prospective study, Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). We studied 227 men and women who were normoglycemic at baseline but hyperglycemic at 3 years (glycemia > or = 6.1 mmol/l or type 2 diabetes). They were matched for sex, age, and body mass index with 227 subjects who remained normoglycemic at 3 years. RESULTS At baseline, the concentration of SHBG was significantly lower in women who subsequently developed hyperglycemia than in those who remained normoglycemic, with no difference for men. In multiple regression, SHBG at baseline was as an independent determinant of plasma adiponectin levels, in both women (P<0.0001) and men (P=0.002). In multivariate conditional logistic regression taking into account physical activity and changes in waist circumference over the follow-up, plasma SHBG remained significantly associated with the development of hyperglycemia in women but not in men. These associations persisted after adjustment for fasting insulinemia, high fasting glucose, and adiponectin levels. CONCLUSIONS These findings suggest that a low SHBG level is a strong risk marker for dysglycemia in women, independently of both adiponectinemia and insulinemia. SHBG may therefore improve the identification of women at risk of diabetes.
Collapse
Affiliation(s)
- F Bonnet
- Endocrinology Unit, Department of Medicine, CHU Rennes, Université Rennes 1, INSERM U625, 35000 Rennes, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Vierron E, Halimi JM, Tichet J, Balkau B, Cogneau J, Giraudeau B. Center effect on ankle-brachial index measurement when using the reference method (Doppler and manometer): results from a large cohort study. Am J Hypertens 2009; 22:718-22. [PMID: 19407803 DOI: 10.1038/ajh.2009.78] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND The ankle-brachial index (ABI) is a simple and noninvasive tool used to detect peripheral arterial disease (PAD). We aimed to assess, in a French multicenter cohort, the center effect associated with arterial pressure (AP) and ABI measurements using the reference method and using a semiautomatic device. METHODS This study included baseline and 9-year follow-up data from 3,664 volunteers of 10 health examination centers of the DESIR (Data from an Epidemiological Study on the Insulin Resistance) syndrome French cohort. Ankle and brachial AP were measured at inclusion by the reference method (a mercury sphygmomanometer coupled with a Doppler probe for ankle measurements) and at 9 years by a semiautomatic device (Omron HEM-705CP). The center effect was assessed by the intraclass correlation coefficient (ICC), ratio of the between-center variance to the total variance of the measurement. RESULTS At inclusion, the sample mean age was 47.5 (s.d. 9.9) years; 49.3% were men. Although ICCs were smaller than 0.05 for brachial AP measurements, they were close to 0.18 and 0.20 for ankle systolic AP (SAP) and ABI measurements, respectively, when the reference method was used. No center effect for measures other than ankle SAP was detected. With the semiautomatic device method, all ICCs, including those for ankle SAP and ABI measurements, were between 0.005 and 0.04. CONCLUSIONS We found an important center effect on ABI measured with a sphygmomanometer and a Doppler probe but not a semiautomatic device. A center effect should be taken into account when planning any multicenter study on ABI measurement.
Collapse
|
47
|
Sparsø T, Bonnefond A, Andersson E, Bouatia-Naji N, Holmkvist J, Wegner L, Grarup N, Gjesing AP, Banasik K, Cavalcanti-Proença C, Marchand M, Vaxillaire M, Charpentier G, Jarvelin MR, Tichet J, Balkau B, Marre M, Lévy-Marchal C, Faerch K, Borch-Johnsen K, Jørgensen T, Madsbad S, Poulsen P, Vaag A, Dina C, Hansen T, Pedersen O, Froguel P. G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. Diabetes 2009; 58:1450-6. [PMID: 19324940 PMCID: PMC2682679 DOI: 10.2337/db08-1660] [Citation(s) in RCA: 112] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
OBJECTIVE Genome-wide association studies have identified several variants within the MTNR1B locus that are associated with fasting plasma glucose (FPG) and type 2 diabetes. We refined the association signal by direct genotyping and examined for associations of the variant displaying the most independent effect on FPG with isolated impaired fasting glycemia (i-IFG), isolated impaired glucose tolerance (i-IGT), type 2 diabetes, and measures of insulin release and peripheral and hepatic insulin sensitivity. RESEARCH DESIGN AND METHODS We examined European-descent participants in the Inter99 study (n = 5,553), in a sample of young healthy Danes (n = 372), in Danish twins (n = 77 elderly and n = 97 young), in additional Danish type 2 diabetic patients (n = 1,626) and control subjects (n = 505), in the Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study (n = 4,656), in the North Finland Birth Cohort 86 (n = 5,258), and in the Haguenau study (n = 1,461). RESULTS The MTNR1B intronic variant, rs10830963, carried most of the effect on FPG and showed the strongest association with FPG (combined P = 5.3 x 10(-31)) and type 2 diabetes. The rs10830963 G-allele increased the risk of i-IFG (odds ratio [OR] 1.64, P = 5.5 x 10(-11)) but not i-IGT. The G-allele was associated with a decreased insulin release after oral and intravenous glucose challenges (P < 0.01) but not after injection of tolbutamide. In elderly twins, the G-allele associated with hepatic insulin resistance (P = 0.017). CONCLUSIONS The G-allele of MTNR1B rs10830963 increases risk of type 2 diabetes through a state of i-IFG and not through i-IGT. The same allele associates with estimates of beta-cell dysfunction and hepatic insulin resistance.
Collapse
|
48
|
Bouatia-Naji N, Marchand M, Cavalcanti-Proença C, Daghmoun S, Durand E, Tichet J, Marre M, Balkau B, Froguel P, Lévy-Marchal C. Smallness for gestational age interacts with high mobility group A2 gene genetic variation to modulate height. Eur J Endocrinol 2009; 160:557-60. [PMID: 19139030 DOI: 10.1530/eje-08-0794] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Height variability is largely under genetic control, although identifying the genetic variants involved has been until recently challenging. Smallness for gestational age (SGA) is a risk factor for adult short stature. Genome-wide association studies have identified a single nucleotide polymorphism (SNP) (rs1042725) in the high mobility group A2 gene (HMGA2) that consistently associates with height variability but its interaction with SGA is unknown. DESIGN We assess the contribution of rs1042725 SNP and height variability in a French population and the impact of rs1042725 on SGA status at birth and height at adulthood in SGA individuals. METHODS We genotyped rs1042725 in 4710 healthy participants from the Data from an Epidemiological Study on the Insulin Resistance syndrome (DESIR) cohort, 743 normal birth weight and 660 SGA individuals from the Haguenau study. RESULTS rs1042725 is associated with increased height in the cohort participants (0.36 cm 95% CI (0.12-0.61) per C allele, P=0.004) but not with the SGA status or birth length. Interestingly, rs1042725 had a stronger effect on height in SGA participants (0.94 cm 95% CI (0.24-1.64) per C allele, P=0.009), especially in men (1.45 cm 95% CI (0.44-2.46) per C allele, P=0.005) in whom rs1042725 may explain 3% of height variability. SGA men carrying at least one C allele copy experienced more frequent catch-up in height (P(add)=0.07; P(dom)=0.03). CONCLUSIONS Our study supports further the contribution of HMGA2 rs1042725 to height variability in European populations and shows an increased effect on height in SGA individuals where this variant favors height catch-up.
Collapse
|
49
|
Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, Launoy G. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009; 100:1230-5. [PMID: 19337253 PMCID: PMC2676539 DOI: 10.1038/sj.bjc.6604996] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
We investigated variations in sensitivity of an immunochemical (I-FOBT) and a guaiac (G-FOBT) faecal occult blood test according to type and location of lesions in an average-risk 50- to 74-year-old population. Screening for colorectal cancer by both non-rehydrated Haemoccult II G-FOBT and Magstream I-FOBT was proposed to a sample of 20 322 subjects. Of the 1615 subjects with at least one positive test, colonoscopy results were available for 1277. A total of 43 invasive cancers and 270 high-risk adenomas were detected. The gain in sensitivity associated with the I-FOBT was calculated using the ratio of sensitivities (RSN) according to type and location of lesions, and amount of bleeding. The gain in sensitivity by using I-FOBT increased from invasive cancers (RSN=1.48 (1.16–4.59)) to high-risk adenomas (RSN=3.32 (2.70–4.07)), and was inversely related to the amount of bleeding. Among cancers, the gain in sensitivity was confined to rectal cancer (RSN=2.09 (1.36–3.20)) and concerned good prognosis cancers, because they involve less bleeding. Among high-risk adenomas, the gain in sensitivity was similar whatever the location. This study suggests that the gain in sensitivity by using an I-FOBT instead of a G-FOBT greatly depends on the location of lesions and the amount of bleeding. Concerning cancer, the gain seems to be confined to rectal cancer.
Collapse
Affiliation(s)
- L Guittet
- Cancers and Populations, ERI3 INSERM, UFR de Médecine, CHU de Caen, Caen, France.
| | | | | | | | | | | | | |
Collapse
|
50
|
Czernichow S, Vergnaud AC, Maillard-Teyssier L, Péneau S, Bertrais S, Méjean C, Vol S, Tichet J, Hercberg S. Trends in the prevalence of obesity in employed adults in central-western France: a population-based study, 1995-2005. Prev Med 2009; 48:262-6. [PMID: 19162065 DOI: 10.1016/j.ypmed.2008.12.016] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2008] [Revised: 12/18/2008] [Accepted: 12/19/2008] [Indexed: 11/19/2022]
Abstract
OBJECTIVE The overall trend of obesity prevalence has increased during the last decades, even in France which has one of the lowest prevalence in Europe. The aim of this study was to assess, according to socioeconomic status (SES), whether a shift in the obesity prevalence trends could be observed since the French National Nutrition and Public Health Program was implemented in 2001. METHODS Standardised cross-sectional repeated population-based data from the French Social Security Health Examination Centers in the central-western region of France (n=339,882). We examined regression slopes (95% CI) of overall and abdominal obesity from 1995 to 2005 according to SES. We also compared slopes within each SES between 1995-2001 and 2001-2005. RESULTS After standardisation to the French age distribution, 6.9% of men and 6.4% of women were obese in 1995 and 8.9% and 8.6% in 2005, respectively. Abdominal adiposity concerned 5.6% of men and 8.5% of women in 1995 and 9.5% and 14.3% in 2005. Obesity prevalence regression slopes between 1995 and 2005 increased in all SES categories, except management professionals in both genders and office/service personnel male who were stable. Significant regression slopes before 2001 became non-significant afterward in office/service personnel males for obesity prevalence; and for abdominal obesity in manual workers women and office/service personnel (p=0.05, in men). CONCLUSIONS Our data confirm the overall epidemic rise in the obesity prevalence trends during the last decade, except in management professionals and office/service personnel men. Obesity prevalence trends in office/service personnel and manual workers women for abdominal obesity were also observed to stabilise since 2001. We could hypothesize that the National Nutrition and Public Health Program may partly be involved in this decreasing trend among office/service personnel mainly. Policymakers should take into account these data to assess the effectiveness of obesity prevention public-health strategies in the future.
Collapse
Affiliation(s)
- Sébastien Czernichow
- Unité de Recherche en Epidémiologie Nutritionnelle, Faculté de medicine SMBH, INSERM U557, INRA U1125, CNAM, UP13, CRNH-IdF, 93017-Bobigny, France.
| | | | | | | | | | | | | | | | | |
Collapse
|